{"id":240126,"date":"2024-05-31T19:30:00","date_gmt":"2024-05-31T11:30:00","guid":{"rendered":"https:\/\/pingtungtimes.com.tw\/?p=240126"},"modified":"2024-05-31T19:30:00","modified_gmt":"2024-05-31T11:30:00","slug":"asco-2024%e7%b2%be%e6%ba%96%e9%86%ab%e5%ad%b8%e5%89%8d%e6%b2%bf%e4%b8%a8illumina%e5%9b%a0%e7%be%8e%e7%b4%8d-%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%8e%a8%e5%8b%95%e5%9f%ba%e5%9b%a0%e6%aa%a2%e6%b8%ac-2","status":"publish","type":"post","link":"https:\/\/pingtungtimes.com.tw\/?p=240126","title":{"rendered":"ASCO 2024\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u4e28Illumina\u56e0\u7f8e\u7d0d \u6700\u65b0\u7814\u7a76\u63a8\u52d5\u57fa\u56e0\u6aa2\u6e2c\u6210\u70ba\u764c\u75c7\u6cbb\u7642\u6a19\u6e96\u6d41\u7a0b"},"content":{"rendered":"<div>\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\u53f0\u53172024\u5e745\u670831\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u5168\u7403\u77da\u76ee\u7684\u816b\u7624\u76db\u6703ASCO 2024\u5c07\u65bc\u7576\u5730\u6642\u95935\u670831\u65e5\u81f36\u67084\u65e5\u5728\u7f8e\u570b\u829d\u52a0\u54e5\u8209\u884c\uff0cIllumina \u56e0\u7f8e\u7d0d14\u9805\u6700\u65b0\u7814\u7a76\u5c07\u4eae\u76f8\u672c\u6b21\u5927\u6703\u3002\u4f5c\u70ba\u5168\u7403\u57fa\u56e0\u5b9a\u5e8f\u548c\u6676\u7247\u6280\u8853\u7684\u9818\u5c0e\u8005\uff0cIllumina\u56e0\u7f8e\u7d0d\u5728ASCO 2024\u4e2d\u651c\u624b\u570b\u969b\u77e5\u540d\u81e8\u5e8a\u5925\u4f34\uff0c\u5c07\u5e36\u4f86\u54ea\u4e9b\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u9032\u5c55\uff0c\u8b93\u6211\u5011\u4eca\u5929\u5148\u7779\u70ba\u5feb\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<p><b>\u4eae\u9ede\uff08<\/b><b>Transform oncology with genomics<\/b><b>\uff09\uff1a<\/b><\/p>\n<ul type=\"disc\">\n<li><b>\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c<\/b><b> (CGP) <\/b><b>\u512a\u65bc\u55ae\u57fa\u56e0\u6aa2\u6e2c<\/b><b> (SGT) <\/b><b>\u7684\u66f4\u591a\u81e8\u5e8a\u5be6\u7528\u6027\u8b49\u64da\uff1b<\/b><\/li>\n<li><b><span id=\"spanHghltac73\">Illumina\u56e0\u7f8e\u7d0d<\/span><\/b> <b>MRD<\/b><b>\uff08\u5fae\u91cf\u6b98\u5b58\u75be\u75c5\uff09\u6aa2\u6e2c\u65b0\u9032\u5c55\uff1b<\/b><\/li>\n<li><b>\u591a\u9805\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff0c\u6d88\u9664\u5e02\u5834\u51c6\u5165\u969c\u7919\uff1b<\/b><\/li>\n<li><b>\u5ee3\u6cdb\u578b<\/b><b>\u8b8a\u7570\u548c\u514d\u75ab\u5206\u6790<\/b><b> (CGIP) <\/b><b>\u57fa\u65bc\u591a\u7d44\u5b78\u8cc7\u6599\u66f4\u597d\u8a55\u4f30\u816b\u7624\u514d\u75ab\uff1b<\/b><\/li>\n<li><b>\u63a2\u7d22\u5168\u57fa\u56e0\u7d44\u6e2c\u5e8f<\/b><b>WGS<\/b><b>\u5728\u816b\u7624\u5e38\u898f\u81e8\u5e8a\u6aa2\u6e2c\u4e2d\u7684\u53ef\u884c\u6027\uff1b<\/b><\/li>\n<\/ul>\n<p>\u540c\u6642\uff0cIllumina \u56e0\u7f8e\u7d0d\u00a0\u5c07\u5728ASCO\u5927\u6703\u73fe\u5834\u8a2d\u7acb\u6524\u4f4d\uff08\u6524\u4f4d\u865f\uff1a35103\uff09\uff0c\u8aa0\u646f\u9080\u8acb\u60a8\u73fe\u5834\u849e\u81e8\u4ea4\u6d41\uff01<\/p>\n<p>Illumina \u56e0\u7f8e\u7d0d\u00a0ASCO 2024 \u7814\u7a76\u84cb\u89bd<\/p>\n<p>1.\u00a0\u00a0\u00a0\u00a0 Performance of comprehensive genomic profiling (CGP) versus single gene testing (SGT) in guideline-recommended biomarker selection in non-small cell lung cancer (NSCLC)<\/p>\n<p>\u975e\u5c0f\u578b\u7d30\u80de\u80ba\u764c\uff08NSCLC\uff09\u4e2d\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u8207\u55ae\u57fa\u56e0\u6aa2\u6e2c\uff08SGT\uff09\u5728\u6307\u5f15\u63a8\u85a6\u751f\u7269\u6a19\u8a18\u7269\u9078\u64c7\u4e2d\u7684\u6027\u80fd\u6bd4\u8f03<\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1a8640<\/li>\n<li>\u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Sarah Cannon Research Institute, Integra<\/li>\n<\/ul>\n<p>2.\u00a0\u00a0\u00a0\u00a0 Paired matched normal sequencing to accurately identify somatic clonal hematopoiesis mutations (CHm) in solid tumor tissue and plasma specimens<\/p>\n<p>\u914d\u5c0d\u6b63\u5e38\u7d44\u7e54\u5b9a\u5e8f\u4ee5\u6e96\u78ba\u8b58\u5225\u5be6\u9ad4\u7624\u7d44\u7e54\u548c\u8840\u6f3f\u6a23\u672c\u4e2d\u7684\u9ad4\u7d30\u80de\u514b\u9686\u9020\u8840\u7a81\u8b8a\uff08CHm\uff09<\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1a 3051<\/li>\n<li>\u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Eurofins, Mayo Clinic<\/li>\n<\/ul>\n<p>3.\u00a0\u00a0\u00a0\u00a0 A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability<\/p>\n<p>\u57fa\u65bc\u591a\u7d44\u5b78\u751f\u7269\u6a19\u8a18\u7269\u7684\u6a5f\u5668\u5b78\u7fd2\u6f14\u7b97\u6cd5\u7528\u65bc\u6aa2\u6e2c\u816b\u7624\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\u6027<\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1a1554<\/li>\n<li>\u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp<\/li>\n<\/ul>\n<p>4.\u00a0\u00a0\u00a0\u00a0 Differences in baseline characteristics and healthcare costs among insured patients with advanced cancer with vs without clinical trial participation\u00a0\u00a0<\/p>\n<p>\u6709\u7121\u81e8\u5e8a\u8a66\u9a57\u53c3\u8207\u7684\u665a\u671f\u764c\u75c7\u4fdd\u96aa\u60a3\u8005\u7684\u57fa\u7dda\u7279\u5fb5\u548c\u91ab\u7642\u6210\u672c\u5dee\u7570<\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1a11154<\/li>\n<li>\u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Optum<\/li>\n<\/ul>\n<p>5.\u00a0\u00a0\u00a0\u00a0 A highly sensitive, low input, and automated assay for molecular residual disease detection (MRD) using whole-genome sequencing (WGS)\u00a0\u00a0<\/p>\n<p>\u57fa\u65bc\u5168\u57fa\u56e0\u7d44\u5b9a\u5e8f\uff08WGS\uff09\u7684\u9ad8\u9748\u654f\u5ea6\u3001\u4f4e\u6a23\u672c\u91cf\u3001\u81ea\u52d5\u5316\u7684\u5fae\u91cf\u6b98\u5b58\u75be\u75c5\uff08MRD\uff09\u6aa2\u6e2c\u65b9\u6cd5<\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1a3060<\/li>\n<li>\u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d<\/li>\n<\/ul>\n<p>6.\u00a0\u00a0\u00a0\u00a0 Comprehensive genomic and immune profiling of non-V600 BRAF-mutated melanomas: Implications for therapeutic strategies beyond BRAF\/MEK inhibitors<\/p>\n<p>\u975eV600 BRAF\u7a81\u8b8a\u9ed1\u8272\u7d20\u7624\u7684\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u548c\u514d\u75ab\u5206\u6790\uff1a\u5c0dBRAF\/MEK\u6291\u5236\u5291\u4ee5\u5916\u6cbb\u7642\u7b56\u7565\u7684\u555f\u793a<\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1ae21544<\/li>\n<li>\u767c\u8868\u55ae\u4f4d\uff1aIIlumina \u56e0\u7f8e\u7d0d, Labcorp<\/li>\n<\/ul>\n<p>7.\u00a0\u00a0\u00a0\u00a0 Multi-specimen comprehensive genomic profiling for diagnostic disambiguation in advanced and metastatic solid tumors Abstract\u00a0<\/p>\n<p>\u591a\u6a23\u672c\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u5728\u665a\u671f\u548c\u8f49\u79fb\u6027\u5be6\u9ad4\u7624\u4e2d\u7684\u8a3a\u65b7\u89e3\u7591<\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1ae15166<\/li>\n<li>\u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp<\/li>\n<\/ul>\n<p>8.\u00a0\u00a0\u00a0\u00a0 Screening for social determinants of health among patients with advanced and metastatic cancer undergoing comprehensive genomic profiling in underserved communities<\/p>\n<p>\u5728\u4e0d\u767c\u9054\u793e\u5340\u4e2d\u63a5\u53d7\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u7684\u665a\u671f\u548c\u8f49\u79fb\u6027\u764c\u75c7\u60a3\u8005\u4e2d\u7be9\u67e5\u5065\u5eb7\u793e\u6703\u6c7a\u5b9a\u56e0\u7d20<\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1ae13545<\/li>\n<li>\u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp<\/li>\n<\/ul>\n<p>9.\u00a0\u00a0\u00a0\u00a0 Implementation of a comprehensive genomic profiling (CGP) panel for precision oncology at a cancer center in <span class=\"xn-location\">Brazil<\/span> \u00a0<\/p>\n<p>\u5728\u5df4\u897f\u4e00\u500b\u764c\u75c7\u4e2d\u5fc3\u5be6\u65bd\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u5c0f\u7d44\u4ee5\u5be6\u73fe\u7cbe\u6e96\u816b\u7624\u5b78<\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1ae23520<\/li>\n<li>\u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, A.C. Camargo Cancer Center<\/li>\n<\/ul>\n<p>10.\u00a0 Feasibility of implementing whole genome sequencing into routine oncology care<\/p>\n<p>\u5c07\u5168\u57fa\u56e0\u7d44\u5b9a\u5e8fWGS\u7d0d\u5165\u816b\u7624\u5e38\u898f\u8b77\u7406\u7684\u53ef\u884c\u6027<\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1ae15181<\/li>\n<li>\u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d\uff0cWeill Cornell<\/li>\n<\/ul>\n<p>11.\u00a0 Real-world costs and outcomes associated with biomarker testing by comprehensive genomic profiling (CGP) and non-CGP approaches among patients with metastatic non-small cell lung cancer (mNSCLC)<\/p>\n<p>\u5728\u8f49\u79fb\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\uff08mNSCLC\uff09\u60a3\u8005\u4e2d\uff0c\u901a\u904e\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u548c\u975eCGP\u65b9\u6cd5\u9032\u884c\u751f\u7269\u6a19\u8a18\u7269\u6aa2\u6e2c\u7684\u771f\u5be6\u4e16\u754c\u6210\u672c\u548c\u7372\u76ca<\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1ae20598<\/li>\n<li>\u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Optum<\/li>\n<\/ul>\n<p>12.\u00a0 CGP-based IO biomarker assessment and treatment utilization across a major US health system<\/p>\n<p>\u5728\u7f8e\u570b\u4e3b\u8981\u91ab\u7642\u7cfb\u7d71\u4e2d\u57fa\u65bcCGP\u7684IO\u816b\u7624\u514d\u75ab\u751f\u7269\u6a19\u8a18\u7269\u8a55\u4f30\u548c\u6cbb\u7642\u5229\u7528\u60c5\u6cc1\u00a0\u00a0<\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1ae23109<\/li>\n<li>\u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, <span class=\"xn-location\">Providence<\/span><\/li>\n<\/ul>\n<p>13.\u00a0 NGS panels&#8217; capture of biomarkers associated with targeted therapies in clinical trials<\/p>\n<p>NGS panel\u6355\u7372\u8207\u81e8\u5e8a\u8a66\u9a57\u4e2d\u6a19\u9776\u6cbb\u7642\u76f8\u95dc\u7684\u751f\u7269\u6a19\u8a18\u7269\u00a0\u00a0<\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1ae13508<\/li>\n<li>\u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d<\/li>\n<\/ul>\n<p>14.\u00a0 Single point of entry to the European precision cancer medicine trial network PRIME-ROSE<\/p>\n<p>\u6b50\u6d32\u7cbe\u6e96\u764c\u75c7\u91ab\u5b78\u8a66\u9a57\u7db2\u8defPRIME-ROSE\u7684\u55ae\u4e00\u5165\u53e3\u9ede<\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1ae23024<\/li>\n<li>\u767c\u8868\u55ae\u4f4d\uff1a IMPRESS Team<\/li>\n<\/ul>\n<p>\u95dc\u65bcIllumina \u56e0\u7f8e\u7d0d<\/p>\n<p>Illumina\u81f4\u529b\u65bc\u63a8\u52d5\u548c\u6fc0\u767c\u57fa\u56e0\u7d44\u5b78\u7684\u767c\u5c55\u800c\u4e0d\u65b7\u6539\u5584\u4eba\u985e\u5065\u5eb7\u3002\u5c08\u6ce8\u5275\u65b0\u4f7f\u6211\u5011\u6210\u70ba\u5168\u7403\u57fa\u56e0\u5b9a\u5e8f\u548c\u6676\u7247\u6280\u8853\u7684\u9818\u5c0e\u8005\uff0c\u4e26\u70ba\u5168\u7403\u7bc4\u570d\u7684\u79d1\u7814\u3001\u81e8\u5e8a\u548c\u61c9\u7528\u5e02\u5834\u5ba2\u6236\u63d0\u4f9b\u5c08\u696d\u670d\u52d9\u3002\u6211\u5011\u7684\u7522\u54c1\u5ee3\u6cdb\u61c9\u7528\u65bc\u751f\u547d\u79d1\u5b78\u3001\u816b\u7624\u5b78\u3001\u751f\u6b96\u4fdd\u5065\u3001\u8fb2\u696d\u53ca\u5176\u4ed6\u65b0\u8208\u9818\u57df\u3002\u6b32\u77ad\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u8a2a\u554f<a href=\"http:\/\/www.illumina.com\/\" target=\"_blank\" rel=\"nofollow noopener\">www.illumina.com<\/a>\u3002<\/p>\n<p>\u5728\u816b\u7624\u9818\u57df\uff0cIllumina\u56e0\u7f8e\u7d0d \u81f4\u529b\u65bc\u63a8\u52d5\u816b\u7624\u500b\u9ad4\u5316\u7684\u8b58\u5225\u8207\u6cbb\u7642\uff0c\u4ee5\u5275\u65b0\u6280\u8853\u52a0\u901f\u816b\u7624\u57fa\u56e0\u7d44\u5b78\u7684\u9769\u65b0\u3002\u6211\u5011\u7684\u6280\u8853\u5ee3\u6cdb\u61c9\u7528\u65bc\u816b\u7624\u57fa\u56e0\u7d44\u5b78\u7814\u7a76\uff0c\u75c5\u7406\u5b78\u8207\u816b\u7624\u81e8\u5e8a\u7814\u7a76\uff0c\u816b\u7624\u4f34\u96a8\u8a3a\u65b7\u4ee5\u53ca\u816b\u7624\u7cbe\u6e96\u91ab\u5b78\u7684\u672a\u4f86\u63a2\u7d22\u3002Illumina\u56e0\u7f8e\u7d0d\u5728\u816b\u7624\u9818\u57df\u7684\u7d42\u6975\u76ee\u6a19\u662f\uff1a\u901a\u904e\u79d1\u5b78\u767c\u73fe\u771f\u6b63\u6539\u8b8a\u816b\u7624\u60a3\u8005\u53ca\u5176\u5bb6\u5ead\u7684\u751f\u6d3b\u3002<\/p>\n<p>\u672c\u6587\u4e2d\u6240\u63d0\u53ca\u7684\u6458\u8981\u5167\u5bb9\u5747\u4f86\u6e90\u65bc\u516c\u958b\u767c\u8868\u7684\u5b78\u8853\u6703\u8b70\u8cc7\u6599\u3002\u6211\u5011\u5df2\u76e1\u529b\u78ba\u4fdd\u6240\u5f15\u7528\u5167\u5bb9\u7684\u6e96\u78ba\u6027\uff0c\u4f46\u4e0d\u5c0d\u5176\u5b8c\u5168\u6e96\u78ba\u6027\u627f\u64d4\u4efb\u4f55\u8cac\u4efb\u3002\u8b80\u8005\u5728\u4f7f\u7528\u6216\u53c3\u8003\u8a72\u5167\u5bb9\u6642\uff0c\u61c9\u81ea\u884c\u6838\u5be6\u76f8\u95dc\u8cc7\u8a0a\u7684\u6e96\u78ba\u6027\uff0c\u4e26\u627f\u64d4\u76f8\u95dc\u98a8\u96aa\u3002\u4e0a\u8ff0\u6458\u8981\u5167\u5bb9\u7684\u7248\u6b0a\u548c\u667a\u6167\u8ca1\u7522\u6b0a\u6b78\u539f\u4f5c\u8005\u6216\u76f8\u95dc\u6a5f\u69cb\u6240\u6709\u3002<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u53f0\u53172024\u5e745\u670831\u65e5 \/\u7f8e&#8230;<\/p>\n","protected":false},"author":16,"featured_media":240127,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[40567],"tags":[],"class_list":["post-240126","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-40567"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASCO 2024\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u4e28Illumina\u56e0\u7f8e\u7d0d \u6700\u65b0\u7814\u7a76\u63a8\u52d5\u57fa\u56e0\u6aa2\u6e2c\u6210\u70ba\u764c\u75c7\u6cbb\u7642\u6a19\u6e96\u6d41\u7a0b - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831<\/title>\n<meta name=\"description\" content=\"\u53f0\u53172024\u5e745\u670831\u65e5 \/\u7f8e\u901a\u793e\/ -- \u5168\u7403\u77da\u76ee\u7684\u816b\u7624\u76db\u6703ASCO 2024\u5c07\u65bc\u7576\u5730\u6642\u95935\u670831\u65e5\u81f36\u67084\u65e5\u5728\u7f8e\u570b\u829d\u52a0\u54e5\u8209\u884c\uff0cIllumina \u56e0\u7f8e\u7d0d14\u9805\u6700\u65b0\u7814\u7a76\u5c07\u4eae\u76f8\u672c\u6b21\u5927\u6703\u3002\u4f5c\u70ba\u5168\u7403\u57fa\u56e0\u5b9a\u5e8f\u548c\u6676\u7247\u6280\u8853\u7684\u9818\u5c0e\u8005\uff0cIllumina\u56e0\u7f8e\u7d0d\u5728ASCO 2024\u4e2d\u651c\u624b\u570b\u969b\u77e5\u540d\u81e8\u5e8a\u5925\u4f34\uff0c\u5c07\u5e36\u4f86\u54ea\u4e9b\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u9032\u5c55\uff0c\u8b93\u6211\u5011\u4eca\u5929\u5148\u7779\u70ba\u5feb\u3002     \u4eae\u9ede\uff08Transform oncology with genomics\uff09\uff1a   \u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c (CGP) \u512a\u65bc\u55ae\u57fa\u56e0\u6aa2\u6e2c (SGT) \u7684\u66f4\u591a\u81e8\u5e8a\u5be6\u7528\u6027\u8b49\u64da\uff1b  Illumina\u56e0\u7f8e\u7d0d MRD\uff08\u5fae\u91cf\u6b98\u5b58\u75be\u75c5\uff09\u6aa2\u6e2c\u65b0\u9032\u5c55\uff1b  \u591a\u9805\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff0c\u6d88\u9664\u5e02\u5834\u51c6\u5165\u969c\u7919\uff1b  \u5ee3\u6cdb\u578b\u8b8a\u7570\u548c\u514d\u75ab\u5206\u6790 (CGIP) \u57fa\u65bc\u591a\u7d44\u5b78\u8cc7\u6599\u66f4\u597d\u8a55\u4f30\u816b\u7624\u514d\u75ab\uff1b  \u63a2\u7d22\u5168\u57fa\u56e0\u7d44\u6e2c\u5e8fWGS\u5728\u816b\u7624\u5e38\u898f\u81e8\u5e8a\u6aa2\u6e2c\u4e2d\u7684\u53ef\u884c\u6027\uff1b  \u540c\u6642\uff0cIllumina \u56e0\u7f8e\u7d0d\u00a0\u5c07\u5728ASCO\u5927\u6703\u73fe\u5834\u8a2d\u7acb\u6524\u4f4d\uff08\u6524\u4f4d\u865f\uff1a35103\uff09\uff0c\u8aa0\u646f\u9080\u8acb\u60a8\u73fe\u5834\u849e\u81e8\u4ea4\u6d41\uff01 Illumina \u56e0\u7f8e\u7d0d\u00a0ASCO 2024 \u7814\u7a76\u84cb\u89bd 1.\u00a0\u00a0\u00a0\u00a0 Performance of comprehensive genomic profiling (CGP) versus single gene testing (SGT) in guideline-recommended biomarker selection in non-small cell lung cancer (NSCLC) \u975e\u5c0f\u578b\u7d30\u80de\u80ba\u764c\uff08NSCLC\uff09\u4e2d\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u8207\u55ae\u57fa\u56e0\u6aa2\u6e2c\uff08SGT\uff09\u5728\u6307\u5f15\u63a8\u85a6\u751f\u7269\u6a19\u8a18\u7269\u9078\u64c7\u4e2d\u7684\u6027\u80fd\u6bd4\u8f03   \u6458\u8981\u7de8\u865f\uff1a8640  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Sarah Cannon Research Institute, Integra  2.\u00a0\u00a0\u00a0\u00a0 Paired matched normal sequencing to accurately identify somatic clonal hematopoiesis mutations (CHm) in solid tumor tissue and plasma specimens \u914d\u5c0d\u6b63\u5e38\u7d44\u7e54\u5b9a\u5e8f\u4ee5\u6e96\u78ba\u8b58\u5225\u5be6\u9ad4\u7624\u7d44\u7e54\u548c\u8840\u6f3f\u6a23\u672c\u4e2d\u7684\u9ad4\u7d30\u80de\u514b\u9686\u9020\u8840\u7a81\u8b8a\uff08CHm\uff09   \u6458\u8981\u7de8\u865f\uff1a 3051  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Eurofins, Mayo Clinic  3.\u00a0\u00a0\u00a0\u00a0 A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability \u57fa\u65bc\u591a\u7d44\u5b78\u751f\u7269\u6a19\u8a18\u7269\u7684\u6a5f\u5668\u5b78\u7fd2\u6f14\u7b97\u6cd5\u7528\u65bc\u6aa2\u6e2c\u816b\u7624\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\u6027   \u6458\u8981\u7de8\u865f\uff1a1554  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp  4.\u00a0\u00a0\u00a0\u00a0 Differences in baseline characteristics and healthcare costs among insured patients with advanced cancer with vs without clinical trial participation\u00a0\u00a0 \u6709\u7121\u81e8\u5e8a\u8a66\u9a57\u53c3\u8207\u7684\u665a\u671f\u764c\u75c7\u4fdd\u96aa\u60a3\u8005\u7684\u57fa\u7dda\u7279\u5fb5\u548c\u91ab\u7642\u6210\u672c\u5dee\u7570   \u6458\u8981\u7de8\u865f\uff1a11154  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Optum  5.\u00a0\u00a0\u00a0\u00a0 A highly sensitive, low input, and automated assay for molecular residual disease detection (MRD) using whole-genome sequencing (WGS)\u00a0\u00a0 \u57fa\u65bc\u5168\u57fa\u56e0\u7d44\u5b9a\u5e8f\uff08WGS\uff09\u7684\u9ad8\u9748\u654f\u5ea6\u3001\u4f4e\u6a23\u672c\u91cf\u3001\u81ea\u52d5\u5316\u7684\u5fae\u91cf\u6b98\u5b58\u75be\u75c5\uff08MRD\uff09\u6aa2\u6e2c\u65b9\u6cd5   \u6458\u8981\u7de8\u865f\uff1a3060  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d  6.\u00a0\u00a0\u00a0\u00a0 Comprehensive genomic and immune profiling of non-V600 BRAF-mutated melanomas: Implications for therapeutic strategies beyond BRAF\/MEK inhibitors \u975eV600 BRAF\u7a81\u8b8a\u9ed1\u8272\u7d20\u7624\u7684\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u548c\u514d\u75ab\u5206\u6790\uff1a\u5c0dBRAF\/MEK\u6291\u5236\u5291\u4ee5\u5916\u6cbb\u7642\u7b56\u7565\u7684\u555f\u793a   \u6458\u8981\u7de8\u865f\uff1ae21544  \u767c\u8868\u55ae\u4f4d\uff1aIIlumina \u56e0\u7f8e\u7d0d, Labcorp  7.\u00a0\u00a0\u00a0\u00a0 Multi-specimen comprehensive genomic profiling for diagnostic disambiguation in advanced and metastatic solid tumors Abstract\u00a0 \u591a\u6a23\u672c\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u5728\u665a\u671f\u548c\u8f49\u79fb\u6027\u5be6\u9ad4\u7624\u4e2d\u7684\u8a3a\u65b7\u89e3\u7591   \u6458\u8981\u7de8\u865f\uff1ae15166  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp  8.\u00a0\u00a0\u00a0\u00a0 Screening for social determinants of health among patients with advanced and metastatic cancer undergoing comprehensive genomic profiling in underserved communities \u5728\u4e0d\u767c\u9054\u793e\u5340\u4e2d\u63a5\u53d7\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u7684\u665a\u671f\u548c\u8f49\u79fb\u6027\u764c\u75c7\u60a3\u8005\u4e2d\u7be9\u67e5\u5065\u5eb7\u793e\u6703\u6c7a\u5b9a\u56e0\u7d20   \u6458\u8981\u7de8\u865f\uff1ae13545  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp  9.\u00a0\u00a0\u00a0\u00a0 Implementation of a comprehensive genomic profiling (CGP) panel for precision oncology at a cancer center in Brazil \u00a0 \u5728\u5df4\u897f\u4e00\u500b\u764c\u75c7\u4e2d\u5fc3\u5be6\u65bd\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u5c0f\u7d44\u4ee5\u5be6\u73fe\u7cbe\u6e96\u816b\u7624\u5b78   \u6458\u8981\u7de8\u865f\uff1ae23520  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, A.C. Camargo Cancer Center  10.\u00a0 Feasibility of implementing whole genome sequencing into routine oncology care \u5c07\u5168\u57fa\u56e0\u7d44\u5b9a\u5e8fWGS\u7d0d\u5165\u816b\u7624\u5e38\u898f\u8b77\u7406\u7684\u53ef\u884c\u6027   \u6458\u8981\u7de8\u865f\uff1ae15181  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d\uff0cWeill Cornell  11.\u00a0 Real-world costs and outcomes associated with biomarker testing by comprehensive genomic profiling (CGP) and non-CGP approaches among patients with metastatic non-small cell lung cancer (mNSCLC) \u5728\u8f49\u79fb\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\uff08mNSCLC\uff09\u60a3\u8005\u4e2d\uff0c\u901a\u904e\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u548c\u975eCGP\u65b9\u6cd5\u9032\u884c\u751f\u7269\u6a19\u8a18\u7269\u6aa2\u6e2c\u7684\u771f\u5be6\u4e16\u754c\u6210\u672c\u548c\u7372\u76ca   \u6458\u8981\u7de8\u865f\uff1ae20598  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Optum  12.\u00a0 CGP-based IO biomarker assessment and treatment utilization across a major US health system \u5728\u7f8e\u570b\u4e3b\u8981\u91ab\u7642\u7cfb\u7d71\u4e2d\u57fa\u65bcCGP\u7684IO\u816b\u7624\u514d\u75ab\u751f\u7269\u6a19\u8a18\u7269\u8a55\u4f30\u548c\u6cbb\u7642\u5229\u7528\u60c5\u6cc1\u00a0\u00a0   \u6458\u8981\u7de8\u865f\uff1ae23109  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Providence  13.\u00a0 NGS panels&#039; capture of biomarkers associated with targeted therapies in clinical trials NGS panel\u6355\u7372\u8207\u81e8\u5e8a\u8a66\u9a57\u4e2d\u6a19\u9776\u6cbb\u7642\u76f8\u95dc\u7684\u751f\u7269\u6a19\u8a18\u7269\u00a0\u00a0   \u6458\u8981\u7de8\u865f\uff1ae13508  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d  14.\u00a0 Single point of entry to the European precision cancer medicine trial network PRIME-ROSE \u6b50\u6d32\u7cbe\u6e96\u764c\u75c7\u91ab\u5b78\u8a66\u9a57\u7db2\u8defPRIME-ROSE\u7684\u55ae\u4e00\u5165\u53e3\u9ede   \u6458\u8981\u7de8\u865f\uff1ae23024  \u767c\u8868\u55ae\u4f4d\uff1a IMPRESS Team  \u95dc\u65bcIllumina \u56e0\u7f8e\u7d0d Illumina\u81f4\u529b\u65bc\u63a8\u52d5\u548c\u6fc0\u767c\u57fa\u56e0\u7d44\u5b78\u7684\u767c\u5c55\u800c\u4e0d\u65b7\u6539\u5584\u4eba\u985e\u5065\u5eb7\u3002\u5c08\u6ce8\u5275\u65b0\u4f7f\u6211\u5011\u6210\u70ba\u5168\u7403\u57fa\u56e0\u5b9a\u5e8f\u548c\u6676\u7247\u6280\u8853\u7684\u9818\u5c0e\u8005\uff0c\u4e26\u70ba\u5168\u7403\u7bc4\u570d\u7684\u79d1\u7814\u3001\u81e8\u5e8a\u548c\u61c9\u7528\u5e02\u5834\u5ba2\u6236\u63d0\u4f9b\u5c08\u696d\u670d\u52d9\u3002\u6211\u5011\u7684\u7522\u54c1\u5ee3\u6cdb\u61c9\u7528\u65bc\u751f\u547d\u79d1\u5b78\u3001\u816b\u7624\u5b78\u3001\u751f\u6b96\u4fdd\u5065\u3001\u8fb2\u696d\u53ca\u5176\u4ed6\u65b0\u8208\u9818\u57df\u3002\u6b32\u77ad\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u8a2a\u554fwww.illumina.com\u3002 \u5728\u816b\u7624\u9818\u57df\uff0cIllumina\u56e0\u7f8e\u7d0d \u81f4\u529b\u65bc\u63a8\u52d5\u816b\u7624\u500b\u9ad4\u5316\u7684\u8b58\u5225\u8207\u6cbb\u7642\uff0c\u4ee5\u5275\u65b0\u6280\u8853\u52a0\u901f\u816b\u7624\u57fa\u56e0\u7d44\u5b78\u7684\u9769\u65b0\u3002\u6211\u5011\u7684\u6280\u8853\u5ee3\u6cdb\u61c9\u7528\u65bc\u816b\u7624\u57fa\u56e0\u7d44\u5b78\u7814\u7a76\uff0c\u75c5\u7406\u5b78\u8207\u816b\u7624\u81e8\u5e8a\u7814\u7a76\uff0c\u816b\u7624\u4f34\u96a8\u8a3a\u65b7\u4ee5\u53ca\u816b\u7624\u7cbe\u6e96\u91ab\u5b78\u7684\u672a\u4f86\u63a2\u7d22\u3002Illumina\u56e0\u7f8e\u7d0d\u5728\u816b\u7624\u9818\u57df\u7684\u7d42\u6975\u76ee\u6a19\u662f\uff1a\u901a\u904e\u79d1\u5b78\u767c\u73fe\u771f\u6b63\u6539\u8b8a\u816b\u7624\u60a3\u8005\u53ca\u5176\u5bb6\u5ead\u7684\u751f\u6d3b\u3002 \u672c\u6587\u4e2d\u6240\u63d0\u53ca\u7684\u6458\u8981\u5167\u5bb9\u5747\u4f86\u6e90\u65bc\u516c\u958b\u767c\u8868\u7684\u5b78\u8853\u6703\u8b70\u8cc7\u6599\u3002\u6211\u5011\u5df2\u76e1\u529b\u78ba\u4fdd\u6240\u5f15\u7528\u5167\u5bb9\u7684\u6e96\u78ba\u6027\uff0c\u4f46\u4e0d\u5c0d\u5176\u5b8c\u5168\u6e96\u78ba\u6027\u627f\u64d4\u4efb\u4f55\u8cac\u4efb\u3002\u8b80\u8005\u5728\u4f7f\u7528\u6216\u53c3\u8003\u8a72\u5167\u5bb9\u6642\uff0c\u61c9\u81ea\u884c\u6838\u5be6\u76f8\u95dc\u8cc7\u8a0a\u7684\u6e96\u78ba\u6027\uff0c\u4e26\u627f\u64d4\u76f8\u95dc\u98a8\u96aa\u3002\u4e0a\u8ff0\u6458\u8981\u5167\u5bb9\u7684\u7248\u6b0a\u548c\u667a\u6167\u8ca1\u7522\u6b0a\u6b78\u539f\u4f5c\u8005\u6216\u76f8\u95dc\u6a5f\u69cb\u6240\u6709\u3002\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pingtungtimes.com.tw\/?p=240126\" \/>\n<meta property=\"og:locale\" content=\"zh_TW\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASCO 2024\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u4e28Illumina\u56e0\u7f8e\u7d0d \u6700\u65b0\u7814\u7a76\u63a8\u52d5\u57fa\u56e0\u6aa2\u6e2c\u6210\u70ba\u764c\u75c7\u6cbb\u7642\u6a19\u6e96\u6d41\u7a0b - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"og:description\" content=\"\u53f0\u53172024\u5e745\u670831\u65e5 \/\u7f8e\u901a\u793e\/ -- \u5168\u7403\u77da\u76ee\u7684\u816b\u7624\u76db\u6703ASCO 2024\u5c07\u65bc\u7576\u5730\u6642\u95935\u670831\u65e5\u81f36\u67084\u65e5\u5728\u7f8e\u570b\u829d\u52a0\u54e5\u8209\u884c\uff0cIllumina \u56e0\u7f8e\u7d0d14\u9805\u6700\u65b0\u7814\u7a76\u5c07\u4eae\u76f8\u672c\u6b21\u5927\u6703\u3002\u4f5c\u70ba\u5168\u7403\u57fa\u56e0\u5b9a\u5e8f\u548c\u6676\u7247\u6280\u8853\u7684\u9818\u5c0e\u8005\uff0cIllumina\u56e0\u7f8e\u7d0d\u5728ASCO 2024\u4e2d\u651c\u624b\u570b\u969b\u77e5\u540d\u81e8\u5e8a\u5925\u4f34\uff0c\u5c07\u5e36\u4f86\u54ea\u4e9b\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u9032\u5c55\uff0c\u8b93\u6211\u5011\u4eca\u5929\u5148\u7779\u70ba\u5feb\u3002     \u4eae\u9ede\uff08Transform oncology with genomics\uff09\uff1a   \u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c (CGP) \u512a\u65bc\u55ae\u57fa\u56e0\u6aa2\u6e2c (SGT) \u7684\u66f4\u591a\u81e8\u5e8a\u5be6\u7528\u6027\u8b49\u64da\uff1b  Illumina\u56e0\u7f8e\u7d0d MRD\uff08\u5fae\u91cf\u6b98\u5b58\u75be\u75c5\uff09\u6aa2\u6e2c\u65b0\u9032\u5c55\uff1b  \u591a\u9805\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff0c\u6d88\u9664\u5e02\u5834\u51c6\u5165\u969c\u7919\uff1b  \u5ee3\u6cdb\u578b\u8b8a\u7570\u548c\u514d\u75ab\u5206\u6790 (CGIP) \u57fa\u65bc\u591a\u7d44\u5b78\u8cc7\u6599\u66f4\u597d\u8a55\u4f30\u816b\u7624\u514d\u75ab\uff1b  \u63a2\u7d22\u5168\u57fa\u56e0\u7d44\u6e2c\u5e8fWGS\u5728\u816b\u7624\u5e38\u898f\u81e8\u5e8a\u6aa2\u6e2c\u4e2d\u7684\u53ef\u884c\u6027\uff1b  \u540c\u6642\uff0cIllumina \u56e0\u7f8e\u7d0d\u00a0\u5c07\u5728ASCO\u5927\u6703\u73fe\u5834\u8a2d\u7acb\u6524\u4f4d\uff08\u6524\u4f4d\u865f\uff1a35103\uff09\uff0c\u8aa0\u646f\u9080\u8acb\u60a8\u73fe\u5834\u849e\u81e8\u4ea4\u6d41\uff01 Illumina \u56e0\u7f8e\u7d0d\u00a0ASCO 2024 \u7814\u7a76\u84cb\u89bd 1.\u00a0\u00a0\u00a0\u00a0 Performance of comprehensive genomic profiling (CGP) versus single gene testing (SGT) in guideline-recommended biomarker selection in non-small cell lung cancer (NSCLC) \u975e\u5c0f\u578b\u7d30\u80de\u80ba\u764c\uff08NSCLC\uff09\u4e2d\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u8207\u55ae\u57fa\u56e0\u6aa2\u6e2c\uff08SGT\uff09\u5728\u6307\u5f15\u63a8\u85a6\u751f\u7269\u6a19\u8a18\u7269\u9078\u64c7\u4e2d\u7684\u6027\u80fd\u6bd4\u8f03   \u6458\u8981\u7de8\u865f\uff1a8640  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Sarah Cannon Research Institute, Integra  2.\u00a0\u00a0\u00a0\u00a0 Paired matched normal sequencing to accurately identify somatic clonal hematopoiesis mutations (CHm) in solid tumor tissue and plasma specimens \u914d\u5c0d\u6b63\u5e38\u7d44\u7e54\u5b9a\u5e8f\u4ee5\u6e96\u78ba\u8b58\u5225\u5be6\u9ad4\u7624\u7d44\u7e54\u548c\u8840\u6f3f\u6a23\u672c\u4e2d\u7684\u9ad4\u7d30\u80de\u514b\u9686\u9020\u8840\u7a81\u8b8a\uff08CHm\uff09   \u6458\u8981\u7de8\u865f\uff1a 3051  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Eurofins, Mayo Clinic  3.\u00a0\u00a0\u00a0\u00a0 A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability \u57fa\u65bc\u591a\u7d44\u5b78\u751f\u7269\u6a19\u8a18\u7269\u7684\u6a5f\u5668\u5b78\u7fd2\u6f14\u7b97\u6cd5\u7528\u65bc\u6aa2\u6e2c\u816b\u7624\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\u6027   \u6458\u8981\u7de8\u865f\uff1a1554  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp  4.\u00a0\u00a0\u00a0\u00a0 Differences in baseline characteristics and healthcare costs among insured patients with advanced cancer with vs without clinical trial participation\u00a0\u00a0 \u6709\u7121\u81e8\u5e8a\u8a66\u9a57\u53c3\u8207\u7684\u665a\u671f\u764c\u75c7\u4fdd\u96aa\u60a3\u8005\u7684\u57fa\u7dda\u7279\u5fb5\u548c\u91ab\u7642\u6210\u672c\u5dee\u7570   \u6458\u8981\u7de8\u865f\uff1a11154  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Optum  5.\u00a0\u00a0\u00a0\u00a0 A highly sensitive, low input, and automated assay for molecular residual disease detection (MRD) using whole-genome sequencing (WGS)\u00a0\u00a0 \u57fa\u65bc\u5168\u57fa\u56e0\u7d44\u5b9a\u5e8f\uff08WGS\uff09\u7684\u9ad8\u9748\u654f\u5ea6\u3001\u4f4e\u6a23\u672c\u91cf\u3001\u81ea\u52d5\u5316\u7684\u5fae\u91cf\u6b98\u5b58\u75be\u75c5\uff08MRD\uff09\u6aa2\u6e2c\u65b9\u6cd5   \u6458\u8981\u7de8\u865f\uff1a3060  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d  6.\u00a0\u00a0\u00a0\u00a0 Comprehensive genomic and immune profiling of non-V600 BRAF-mutated melanomas: Implications for therapeutic strategies beyond BRAF\/MEK inhibitors \u975eV600 BRAF\u7a81\u8b8a\u9ed1\u8272\u7d20\u7624\u7684\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u548c\u514d\u75ab\u5206\u6790\uff1a\u5c0dBRAF\/MEK\u6291\u5236\u5291\u4ee5\u5916\u6cbb\u7642\u7b56\u7565\u7684\u555f\u793a   \u6458\u8981\u7de8\u865f\uff1ae21544  \u767c\u8868\u55ae\u4f4d\uff1aIIlumina \u56e0\u7f8e\u7d0d, Labcorp  7.\u00a0\u00a0\u00a0\u00a0 Multi-specimen comprehensive genomic profiling for diagnostic disambiguation in advanced and metastatic solid tumors Abstract\u00a0 \u591a\u6a23\u672c\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u5728\u665a\u671f\u548c\u8f49\u79fb\u6027\u5be6\u9ad4\u7624\u4e2d\u7684\u8a3a\u65b7\u89e3\u7591   \u6458\u8981\u7de8\u865f\uff1ae15166  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp  8.\u00a0\u00a0\u00a0\u00a0 Screening for social determinants of health among patients with advanced and metastatic cancer undergoing comprehensive genomic profiling in underserved communities \u5728\u4e0d\u767c\u9054\u793e\u5340\u4e2d\u63a5\u53d7\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u7684\u665a\u671f\u548c\u8f49\u79fb\u6027\u764c\u75c7\u60a3\u8005\u4e2d\u7be9\u67e5\u5065\u5eb7\u793e\u6703\u6c7a\u5b9a\u56e0\u7d20   \u6458\u8981\u7de8\u865f\uff1ae13545  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp  9.\u00a0\u00a0\u00a0\u00a0 Implementation of a comprehensive genomic profiling (CGP) panel for precision oncology at a cancer center in Brazil \u00a0 \u5728\u5df4\u897f\u4e00\u500b\u764c\u75c7\u4e2d\u5fc3\u5be6\u65bd\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u5c0f\u7d44\u4ee5\u5be6\u73fe\u7cbe\u6e96\u816b\u7624\u5b78   \u6458\u8981\u7de8\u865f\uff1ae23520  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, A.C. Camargo Cancer Center  10.\u00a0 Feasibility of implementing whole genome sequencing into routine oncology care \u5c07\u5168\u57fa\u56e0\u7d44\u5b9a\u5e8fWGS\u7d0d\u5165\u816b\u7624\u5e38\u898f\u8b77\u7406\u7684\u53ef\u884c\u6027   \u6458\u8981\u7de8\u865f\uff1ae15181  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d\uff0cWeill Cornell  11.\u00a0 Real-world costs and outcomes associated with biomarker testing by comprehensive genomic profiling (CGP) and non-CGP approaches among patients with metastatic non-small cell lung cancer (mNSCLC) \u5728\u8f49\u79fb\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\uff08mNSCLC\uff09\u60a3\u8005\u4e2d\uff0c\u901a\u904e\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u548c\u975eCGP\u65b9\u6cd5\u9032\u884c\u751f\u7269\u6a19\u8a18\u7269\u6aa2\u6e2c\u7684\u771f\u5be6\u4e16\u754c\u6210\u672c\u548c\u7372\u76ca   \u6458\u8981\u7de8\u865f\uff1ae20598  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Optum  12.\u00a0 CGP-based IO biomarker assessment and treatment utilization across a major US health system \u5728\u7f8e\u570b\u4e3b\u8981\u91ab\u7642\u7cfb\u7d71\u4e2d\u57fa\u65bcCGP\u7684IO\u816b\u7624\u514d\u75ab\u751f\u7269\u6a19\u8a18\u7269\u8a55\u4f30\u548c\u6cbb\u7642\u5229\u7528\u60c5\u6cc1\u00a0\u00a0   \u6458\u8981\u7de8\u865f\uff1ae23109  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Providence  13.\u00a0 NGS panels&#039; capture of biomarkers associated with targeted therapies in clinical trials NGS panel\u6355\u7372\u8207\u81e8\u5e8a\u8a66\u9a57\u4e2d\u6a19\u9776\u6cbb\u7642\u76f8\u95dc\u7684\u751f\u7269\u6a19\u8a18\u7269\u00a0\u00a0   \u6458\u8981\u7de8\u865f\uff1ae13508  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d  14.\u00a0 Single point of entry to the European precision cancer medicine trial network PRIME-ROSE \u6b50\u6d32\u7cbe\u6e96\u764c\u75c7\u91ab\u5b78\u8a66\u9a57\u7db2\u8defPRIME-ROSE\u7684\u55ae\u4e00\u5165\u53e3\u9ede   \u6458\u8981\u7de8\u865f\uff1ae23024  \u767c\u8868\u55ae\u4f4d\uff1a IMPRESS Team  \u95dc\u65bcIllumina \u56e0\u7f8e\u7d0d Illumina\u81f4\u529b\u65bc\u63a8\u52d5\u548c\u6fc0\u767c\u57fa\u56e0\u7d44\u5b78\u7684\u767c\u5c55\u800c\u4e0d\u65b7\u6539\u5584\u4eba\u985e\u5065\u5eb7\u3002\u5c08\u6ce8\u5275\u65b0\u4f7f\u6211\u5011\u6210\u70ba\u5168\u7403\u57fa\u56e0\u5b9a\u5e8f\u548c\u6676\u7247\u6280\u8853\u7684\u9818\u5c0e\u8005\uff0c\u4e26\u70ba\u5168\u7403\u7bc4\u570d\u7684\u79d1\u7814\u3001\u81e8\u5e8a\u548c\u61c9\u7528\u5e02\u5834\u5ba2\u6236\u63d0\u4f9b\u5c08\u696d\u670d\u52d9\u3002\u6211\u5011\u7684\u7522\u54c1\u5ee3\u6cdb\u61c9\u7528\u65bc\u751f\u547d\u79d1\u5b78\u3001\u816b\u7624\u5b78\u3001\u751f\u6b96\u4fdd\u5065\u3001\u8fb2\u696d\u53ca\u5176\u4ed6\u65b0\u8208\u9818\u57df\u3002\u6b32\u77ad\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u8a2a\u554fwww.illumina.com\u3002 \u5728\u816b\u7624\u9818\u57df\uff0cIllumina\u56e0\u7f8e\u7d0d \u81f4\u529b\u65bc\u63a8\u52d5\u816b\u7624\u500b\u9ad4\u5316\u7684\u8b58\u5225\u8207\u6cbb\u7642\uff0c\u4ee5\u5275\u65b0\u6280\u8853\u52a0\u901f\u816b\u7624\u57fa\u56e0\u7d44\u5b78\u7684\u9769\u65b0\u3002\u6211\u5011\u7684\u6280\u8853\u5ee3\u6cdb\u61c9\u7528\u65bc\u816b\u7624\u57fa\u56e0\u7d44\u5b78\u7814\u7a76\uff0c\u75c5\u7406\u5b78\u8207\u816b\u7624\u81e8\u5e8a\u7814\u7a76\uff0c\u816b\u7624\u4f34\u96a8\u8a3a\u65b7\u4ee5\u53ca\u816b\u7624\u7cbe\u6e96\u91ab\u5b78\u7684\u672a\u4f86\u63a2\u7d22\u3002Illumina\u56e0\u7f8e\u7d0d\u5728\u816b\u7624\u9818\u57df\u7684\u7d42\u6975\u76ee\u6a19\u662f\uff1a\u901a\u904e\u79d1\u5b78\u767c\u73fe\u771f\u6b63\u6539\u8b8a\u816b\u7624\u60a3\u8005\u53ca\u5176\u5bb6\u5ead\u7684\u751f\u6d3b\u3002 \u672c\u6587\u4e2d\u6240\u63d0\u53ca\u7684\u6458\u8981\u5167\u5bb9\u5747\u4f86\u6e90\u65bc\u516c\u958b\u767c\u8868\u7684\u5b78\u8853\u6703\u8b70\u8cc7\u6599\u3002\u6211\u5011\u5df2\u76e1\u529b\u78ba\u4fdd\u6240\u5f15\u7528\u5167\u5bb9\u7684\u6e96\u78ba\u6027\uff0c\u4f46\u4e0d\u5c0d\u5176\u5b8c\u5168\u6e96\u78ba\u6027\u627f\u64d4\u4efb\u4f55\u8cac\u4efb\u3002\u8b80\u8005\u5728\u4f7f\u7528\u6216\u53c3\u8003\u8a72\u5167\u5bb9\u6642\uff0c\u61c9\u81ea\u884c\u6838\u5be6\u76f8\u95dc\u8cc7\u8a0a\u7684\u6e96\u78ba\u6027\uff0c\u4e26\u627f\u64d4\u76f8\u95dc\u98a8\u96aa\u3002\u4e0a\u8ff0\u6458\u8981\u5167\u5bb9\u7684\u7248\u6b0a\u548c\u667a\u6167\u8ca1\u7522\u6b0a\u6b78\u539f\u4f5c\u8005\u6216\u76f8\u95dc\u6a5f\u69cb\u6240\u6709\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pingtungtimes.com.tw\/?p=240126\" \/>\n<meta property=\"og:site_name\" content=\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pingtungnews\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-31T11:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2024\/05\/illumina_full_logo_RGB_pumpkin_Logo-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"97\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u7f8e\u901a\u793e\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005:\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u7f8e\u901a\u793e\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u4f30\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=240126#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=240126\"},\"author\":{\"name\":\"\u7f8e\u901a\u793e\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\"},\"headline\":\"ASCO 2024\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u4e28Illumina\u56e0\u7f8e\u7d0d \u6700\u65b0\u7814\u7a76\u63a8\u52d5\u57fa\u56e0\u6aa2\u6e2c\u6210\u70ba\u764c\u75c7\u6cbb\u7642\u6a19\u6e96\u6d41\u7a0b\",\"datePublished\":\"2024-05-31T11:30:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=240126\"},\"wordCount\":327,\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=240126#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/illumina_full_logo_RGB_pumpkin_Logo-1.jpg\",\"articleSection\":[\"\u7f8e\u901a\u793e\"],\"inLanguage\":\"zh-TW\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=240126\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=240126\",\"name\":\"ASCO 2024\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u4e28Illumina\u56e0\u7f8e\u7d0d \u6700\u65b0\u7814\u7a76\u63a8\u52d5\u57fa\u56e0\u6aa2\u6e2c\u6210\u70ba\u764c\u75c7\u6cbb\u7642\u6a19\u6e96\u6d41\u7a0b - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=240126#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=240126#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/illumina_full_logo_RGB_pumpkin_Logo-1.jpg\",\"datePublished\":\"2024-05-31T11:30:00+00:00\",\"description\":\"\u53f0\u53172024\u5e745\u670831\u65e5 \\\/\u7f8e\u901a\u793e\\\/ -- \u5168\u7403\u77da\u76ee\u7684\u816b\u7624\u76db\u6703ASCO 2024\u5c07\u65bc\u7576\u5730\u6642\u95935\u670831\u65e5\u81f36\u67084\u65e5\u5728\u7f8e\u570b\u829d\u52a0\u54e5\u8209\u884c\uff0cIllumina \u56e0\u7f8e\u7d0d14\u9805\u6700\u65b0\u7814\u7a76\u5c07\u4eae\u76f8\u672c\u6b21\u5927\u6703\u3002\u4f5c\u70ba\u5168\u7403\u57fa\u56e0\u5b9a\u5e8f\u548c\u6676\u7247\u6280\u8853\u7684\u9818\u5c0e\u8005\uff0cIllumina\u56e0\u7f8e\u7d0d\u5728ASCO 2024\u4e2d\u651c\u624b\u570b\u969b\u77e5\u540d\u81e8\u5e8a\u5925\u4f34\uff0c\u5c07\u5e36\u4f86\u54ea\u4e9b\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u9032\u5c55\uff0c\u8b93\u6211\u5011\u4eca\u5929\u5148\u7779\u70ba\u5feb\u3002 \u4eae\u9ede\uff08Transform oncology with genomics\uff09\uff1a \u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c (CGP) \u512a\u65bc\u55ae\u57fa\u56e0\u6aa2\u6e2c (SGT) \u7684\u66f4\u591a\u81e8\u5e8a\u5be6\u7528\u6027\u8b49\u64da\uff1b Illumina\u56e0\u7f8e\u7d0d MRD\uff08\u5fae\u91cf\u6b98\u5b58\u75be\u75c5\uff09\u6aa2\u6e2c\u65b0\u9032\u5c55\uff1b \u591a\u9805\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff0c\u6d88\u9664\u5e02\u5834\u51c6\u5165\u969c\u7919\uff1b \u5ee3\u6cdb\u578b\u8b8a\u7570\u548c\u514d\u75ab\u5206\u6790 (CGIP) \u57fa\u65bc\u591a\u7d44\u5b78\u8cc7\u6599\u66f4\u597d\u8a55\u4f30\u816b\u7624\u514d\u75ab\uff1b \u63a2\u7d22\u5168\u57fa\u56e0\u7d44\u6e2c\u5e8fWGS\u5728\u816b\u7624\u5e38\u898f\u81e8\u5e8a\u6aa2\u6e2c\u4e2d\u7684\u53ef\u884c\u6027\uff1b \u540c\u6642\uff0cIllumina \u56e0\u7f8e\u7d0d\u00a0\u5c07\u5728ASCO\u5927\u6703\u73fe\u5834\u8a2d\u7acb\u6524\u4f4d\uff08\u6524\u4f4d\u865f\uff1a35103\uff09\uff0c\u8aa0\u646f\u9080\u8acb\u60a8\u73fe\u5834\u849e\u81e8\u4ea4\u6d41\uff01 Illumina \u56e0\u7f8e\u7d0d\u00a0ASCO 2024 \u7814\u7a76\u84cb\u89bd 1.\u00a0\u00a0\u00a0\u00a0 Performance of comprehensive genomic profiling (CGP) versus single gene testing (SGT) in guideline-recommended biomarker selection in non-small cell lung cancer (NSCLC) \u975e\u5c0f\u578b\u7d30\u80de\u80ba\u764c\uff08NSCLC\uff09\u4e2d\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u8207\u55ae\u57fa\u56e0\u6aa2\u6e2c\uff08SGT\uff09\u5728\u6307\u5f15\u63a8\u85a6\u751f\u7269\u6a19\u8a18\u7269\u9078\u64c7\u4e2d\u7684\u6027\u80fd\u6bd4\u8f03 \u6458\u8981\u7de8\u865f\uff1a8640 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Sarah Cannon Research Institute, Integra 2.\u00a0\u00a0\u00a0\u00a0 Paired matched normal sequencing to accurately identify somatic clonal hematopoiesis mutations (CHm) in solid tumor tissue and plasma specimens \u914d\u5c0d\u6b63\u5e38\u7d44\u7e54\u5b9a\u5e8f\u4ee5\u6e96\u78ba\u8b58\u5225\u5be6\u9ad4\u7624\u7d44\u7e54\u548c\u8840\u6f3f\u6a23\u672c\u4e2d\u7684\u9ad4\u7d30\u80de\u514b\u9686\u9020\u8840\u7a81\u8b8a\uff08CHm\uff09 \u6458\u8981\u7de8\u865f\uff1a 3051 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Eurofins, Mayo Clinic 3.\u00a0\u00a0\u00a0\u00a0 A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability \u57fa\u65bc\u591a\u7d44\u5b78\u751f\u7269\u6a19\u8a18\u7269\u7684\u6a5f\u5668\u5b78\u7fd2\u6f14\u7b97\u6cd5\u7528\u65bc\u6aa2\u6e2c\u816b\u7624\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\u6027 \u6458\u8981\u7de8\u865f\uff1a1554 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp 4.\u00a0\u00a0\u00a0\u00a0 Differences in baseline characteristics and healthcare costs among insured patients with advanced cancer with vs without clinical trial participation\u00a0\u00a0 \u6709\u7121\u81e8\u5e8a\u8a66\u9a57\u53c3\u8207\u7684\u665a\u671f\u764c\u75c7\u4fdd\u96aa\u60a3\u8005\u7684\u57fa\u7dda\u7279\u5fb5\u548c\u91ab\u7642\u6210\u672c\u5dee\u7570 \u6458\u8981\u7de8\u865f\uff1a11154 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Optum 5.\u00a0\u00a0\u00a0\u00a0 A highly sensitive, low input, and automated assay for molecular residual disease detection (MRD) using whole-genome sequencing (WGS)\u00a0\u00a0 \u57fa\u65bc\u5168\u57fa\u56e0\u7d44\u5b9a\u5e8f\uff08WGS\uff09\u7684\u9ad8\u9748\u654f\u5ea6\u3001\u4f4e\u6a23\u672c\u91cf\u3001\u81ea\u52d5\u5316\u7684\u5fae\u91cf\u6b98\u5b58\u75be\u75c5\uff08MRD\uff09\u6aa2\u6e2c\u65b9\u6cd5 \u6458\u8981\u7de8\u865f\uff1a3060 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d 6.\u00a0\u00a0\u00a0\u00a0 Comprehensive genomic and immune profiling of non-V600 BRAF-mutated melanomas: Implications for therapeutic strategies beyond BRAF\\\/MEK inhibitors \u975eV600 BRAF\u7a81\u8b8a\u9ed1\u8272\u7d20\u7624\u7684\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u548c\u514d\u75ab\u5206\u6790\uff1a\u5c0dBRAF\\\/MEK\u6291\u5236\u5291\u4ee5\u5916\u6cbb\u7642\u7b56\u7565\u7684\u555f\u793a \u6458\u8981\u7de8\u865f\uff1ae21544 \u767c\u8868\u55ae\u4f4d\uff1aIIlumina \u56e0\u7f8e\u7d0d, Labcorp 7.\u00a0\u00a0\u00a0\u00a0 Multi-specimen comprehensive genomic profiling for diagnostic disambiguation in advanced and metastatic solid tumors Abstract\u00a0 \u591a\u6a23\u672c\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u5728\u665a\u671f\u548c\u8f49\u79fb\u6027\u5be6\u9ad4\u7624\u4e2d\u7684\u8a3a\u65b7\u89e3\u7591 \u6458\u8981\u7de8\u865f\uff1ae15166 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp 8.\u00a0\u00a0\u00a0\u00a0 Screening for social determinants of health among patients with advanced and metastatic cancer undergoing comprehensive genomic profiling in underserved communities \u5728\u4e0d\u767c\u9054\u793e\u5340\u4e2d\u63a5\u53d7\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u7684\u665a\u671f\u548c\u8f49\u79fb\u6027\u764c\u75c7\u60a3\u8005\u4e2d\u7be9\u67e5\u5065\u5eb7\u793e\u6703\u6c7a\u5b9a\u56e0\u7d20 \u6458\u8981\u7de8\u865f\uff1ae13545 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp 9.\u00a0\u00a0\u00a0\u00a0 Implementation of a comprehensive genomic profiling (CGP) panel for precision oncology at a cancer center in Brazil \u00a0 \u5728\u5df4\u897f\u4e00\u500b\u764c\u75c7\u4e2d\u5fc3\u5be6\u65bd\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u5c0f\u7d44\u4ee5\u5be6\u73fe\u7cbe\u6e96\u816b\u7624\u5b78 \u6458\u8981\u7de8\u865f\uff1ae23520 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, A.C. Camargo Cancer Center 10.\u00a0 Feasibility of implementing whole genome sequencing into routine oncology care \u5c07\u5168\u57fa\u56e0\u7d44\u5b9a\u5e8fWGS\u7d0d\u5165\u816b\u7624\u5e38\u898f\u8b77\u7406\u7684\u53ef\u884c\u6027 \u6458\u8981\u7de8\u865f\uff1ae15181 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d\uff0cWeill Cornell 11.\u00a0 Real-world costs and outcomes associated with biomarker testing by comprehensive genomic profiling (CGP) and non-CGP approaches among patients with metastatic non-small cell lung cancer (mNSCLC) \u5728\u8f49\u79fb\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\uff08mNSCLC\uff09\u60a3\u8005\u4e2d\uff0c\u901a\u904e\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u548c\u975eCGP\u65b9\u6cd5\u9032\u884c\u751f\u7269\u6a19\u8a18\u7269\u6aa2\u6e2c\u7684\u771f\u5be6\u4e16\u754c\u6210\u672c\u548c\u7372\u76ca \u6458\u8981\u7de8\u865f\uff1ae20598 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Optum 12.\u00a0 CGP-based IO biomarker assessment and treatment utilization across a major US health system \u5728\u7f8e\u570b\u4e3b\u8981\u91ab\u7642\u7cfb\u7d71\u4e2d\u57fa\u65bcCGP\u7684IO\u816b\u7624\u514d\u75ab\u751f\u7269\u6a19\u8a18\u7269\u8a55\u4f30\u548c\u6cbb\u7642\u5229\u7528\u60c5\u6cc1\u00a0\u00a0 \u6458\u8981\u7de8\u865f\uff1ae23109 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Providence 13.\u00a0 NGS panels' capture of biomarkers associated with targeted therapies in clinical trials NGS panel\u6355\u7372\u8207\u81e8\u5e8a\u8a66\u9a57\u4e2d\u6a19\u9776\u6cbb\u7642\u76f8\u95dc\u7684\u751f\u7269\u6a19\u8a18\u7269\u00a0\u00a0 \u6458\u8981\u7de8\u865f\uff1ae13508 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d 14.\u00a0 Single point of entry to the European precision cancer medicine trial network PRIME-ROSE \u6b50\u6d32\u7cbe\u6e96\u764c\u75c7\u91ab\u5b78\u8a66\u9a57\u7db2\u8defPRIME-ROSE\u7684\u55ae\u4e00\u5165\u53e3\u9ede \u6458\u8981\u7de8\u865f\uff1ae23024 \u767c\u8868\u55ae\u4f4d\uff1a IMPRESS Team \u95dc\u65bcIllumina \u56e0\u7f8e\u7d0d Illumina\u81f4\u529b\u65bc\u63a8\u52d5\u548c\u6fc0\u767c\u57fa\u56e0\u7d44\u5b78\u7684\u767c\u5c55\u800c\u4e0d\u65b7\u6539\u5584\u4eba\u985e\u5065\u5eb7\u3002\u5c08\u6ce8\u5275\u65b0\u4f7f\u6211\u5011\u6210\u70ba\u5168\u7403\u57fa\u56e0\u5b9a\u5e8f\u548c\u6676\u7247\u6280\u8853\u7684\u9818\u5c0e\u8005\uff0c\u4e26\u70ba\u5168\u7403\u7bc4\u570d\u7684\u79d1\u7814\u3001\u81e8\u5e8a\u548c\u61c9\u7528\u5e02\u5834\u5ba2\u6236\u63d0\u4f9b\u5c08\u696d\u670d\u52d9\u3002\u6211\u5011\u7684\u7522\u54c1\u5ee3\u6cdb\u61c9\u7528\u65bc\u751f\u547d\u79d1\u5b78\u3001\u816b\u7624\u5b78\u3001\u751f\u6b96\u4fdd\u5065\u3001\u8fb2\u696d\u53ca\u5176\u4ed6\u65b0\u8208\u9818\u57df\u3002\u6b32\u77ad\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u8a2a\u554fwww.illumina.com\u3002 \u5728\u816b\u7624\u9818\u57df\uff0cIllumina\u56e0\u7f8e\u7d0d \u81f4\u529b\u65bc\u63a8\u52d5\u816b\u7624\u500b\u9ad4\u5316\u7684\u8b58\u5225\u8207\u6cbb\u7642\uff0c\u4ee5\u5275\u65b0\u6280\u8853\u52a0\u901f\u816b\u7624\u57fa\u56e0\u7d44\u5b78\u7684\u9769\u65b0\u3002\u6211\u5011\u7684\u6280\u8853\u5ee3\u6cdb\u61c9\u7528\u65bc\u816b\u7624\u57fa\u56e0\u7d44\u5b78\u7814\u7a76\uff0c\u75c5\u7406\u5b78\u8207\u816b\u7624\u81e8\u5e8a\u7814\u7a76\uff0c\u816b\u7624\u4f34\u96a8\u8a3a\u65b7\u4ee5\u53ca\u816b\u7624\u7cbe\u6e96\u91ab\u5b78\u7684\u672a\u4f86\u63a2\u7d22\u3002Illumina\u56e0\u7f8e\u7d0d\u5728\u816b\u7624\u9818\u57df\u7684\u7d42\u6975\u76ee\u6a19\u662f\uff1a\u901a\u904e\u79d1\u5b78\u767c\u73fe\u771f\u6b63\u6539\u8b8a\u816b\u7624\u60a3\u8005\u53ca\u5176\u5bb6\u5ead\u7684\u751f\u6d3b\u3002 \u672c\u6587\u4e2d\u6240\u63d0\u53ca\u7684\u6458\u8981\u5167\u5bb9\u5747\u4f86\u6e90\u65bc\u516c\u958b\u767c\u8868\u7684\u5b78\u8853\u6703\u8b70\u8cc7\u6599\u3002\u6211\u5011\u5df2\u76e1\u529b\u78ba\u4fdd\u6240\u5f15\u7528\u5167\u5bb9\u7684\u6e96\u78ba\u6027\uff0c\u4f46\u4e0d\u5c0d\u5176\u5b8c\u5168\u6e96\u78ba\u6027\u627f\u64d4\u4efb\u4f55\u8cac\u4efb\u3002\u8b80\u8005\u5728\u4f7f\u7528\u6216\u53c3\u8003\u8a72\u5167\u5bb9\u6642\uff0c\u61c9\u81ea\u884c\u6838\u5be6\u76f8\u95dc\u8cc7\u8a0a\u7684\u6e96\u78ba\u6027\uff0c\u4e26\u627f\u64d4\u76f8\u95dc\u98a8\u96aa\u3002\u4e0a\u8ff0\u6458\u8981\u5167\u5bb9\u7684\u7248\u6b0a\u548c\u667a\u6167\u8ca1\u7522\u6b0a\u6b78\u539f\u4f5c\u8005\u6216\u76f8\u95dc\u6a5f\u69cb\u6240\u6709\u3002\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=240126#breadcrumb\"},\"inLanguage\":\"zh-TW\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=240126\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=240126#primaryimage\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/illumina_full_logo_RGB_pumpkin_Logo-1.jpg\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/illumina_full_logo_RGB_pumpkin_Logo-1.jpg\",\"width\":400,\"height\":97},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=240126#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASCO 2024\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u4e28Illumina\u56e0\u7f8e\u7d0d \u6700\u65b0\u7814\u7a76\u63a8\u52d5\u57fa\u56e0\u6aa2\u6e2c\u6210\u70ba\u764c\u75c7\u6cbb\u7642\u6a19\u6e96\u6d41\u7a0b\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"description\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4\",\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-TW\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"width\":150,\"height\":150,\"caption\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pingtungnews\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\",\"name\":\"\u7f8e\u901a\u793e\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"caption\":\"\u7f8e\u901a\u793e\"},\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?author=16\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASCO 2024\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u4e28Illumina\u56e0\u7f8e\u7d0d \u6700\u65b0\u7814\u7a76\u63a8\u52d5\u57fa\u56e0\u6aa2\u6e2c\u6210\u70ba\u764c\u75c7\u6cbb\u7642\u6a19\u6e96\u6d41\u7a0b - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u53f0\u53172024\u5e745\u670831\u65e5 \/\u7f8e\u901a\u793e\/ -- \u5168\u7403\u77da\u76ee\u7684\u816b\u7624\u76db\u6703ASCO 2024\u5c07\u65bc\u7576\u5730\u6642\u95935\u670831\u65e5\u81f36\u67084\u65e5\u5728\u7f8e\u570b\u829d\u52a0\u54e5\u8209\u884c\uff0cIllumina \u56e0\u7f8e\u7d0d14\u9805\u6700\u65b0\u7814\u7a76\u5c07\u4eae\u76f8\u672c\u6b21\u5927\u6703\u3002\u4f5c\u70ba\u5168\u7403\u57fa\u56e0\u5b9a\u5e8f\u548c\u6676\u7247\u6280\u8853\u7684\u9818\u5c0e\u8005\uff0cIllumina\u56e0\u7f8e\u7d0d\u5728ASCO 2024\u4e2d\u651c\u624b\u570b\u969b\u77e5\u540d\u81e8\u5e8a\u5925\u4f34\uff0c\u5c07\u5e36\u4f86\u54ea\u4e9b\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u9032\u5c55\uff0c\u8b93\u6211\u5011\u4eca\u5929\u5148\u7779\u70ba\u5feb\u3002     \u4eae\u9ede\uff08Transform oncology with genomics\uff09\uff1a   \u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c (CGP) \u512a\u65bc\u55ae\u57fa\u56e0\u6aa2\u6e2c (SGT) \u7684\u66f4\u591a\u81e8\u5e8a\u5be6\u7528\u6027\u8b49\u64da\uff1b  Illumina\u56e0\u7f8e\u7d0d MRD\uff08\u5fae\u91cf\u6b98\u5b58\u75be\u75c5\uff09\u6aa2\u6e2c\u65b0\u9032\u5c55\uff1b  \u591a\u9805\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff0c\u6d88\u9664\u5e02\u5834\u51c6\u5165\u969c\u7919\uff1b  \u5ee3\u6cdb\u578b\u8b8a\u7570\u548c\u514d\u75ab\u5206\u6790 (CGIP) \u57fa\u65bc\u591a\u7d44\u5b78\u8cc7\u6599\u66f4\u597d\u8a55\u4f30\u816b\u7624\u514d\u75ab\uff1b  \u63a2\u7d22\u5168\u57fa\u56e0\u7d44\u6e2c\u5e8fWGS\u5728\u816b\u7624\u5e38\u898f\u81e8\u5e8a\u6aa2\u6e2c\u4e2d\u7684\u53ef\u884c\u6027\uff1b  \u540c\u6642\uff0cIllumina \u56e0\u7f8e\u7d0d\u00a0\u5c07\u5728ASCO\u5927\u6703\u73fe\u5834\u8a2d\u7acb\u6524\u4f4d\uff08\u6524\u4f4d\u865f\uff1a35103\uff09\uff0c\u8aa0\u646f\u9080\u8acb\u60a8\u73fe\u5834\u849e\u81e8\u4ea4\u6d41\uff01 Illumina \u56e0\u7f8e\u7d0d\u00a0ASCO 2024 \u7814\u7a76\u84cb\u89bd 1.\u00a0\u00a0\u00a0\u00a0 Performance of comprehensive genomic profiling (CGP) versus single gene testing (SGT) in guideline-recommended biomarker selection in non-small cell lung cancer (NSCLC) \u975e\u5c0f\u578b\u7d30\u80de\u80ba\u764c\uff08NSCLC\uff09\u4e2d\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u8207\u55ae\u57fa\u56e0\u6aa2\u6e2c\uff08SGT\uff09\u5728\u6307\u5f15\u63a8\u85a6\u751f\u7269\u6a19\u8a18\u7269\u9078\u64c7\u4e2d\u7684\u6027\u80fd\u6bd4\u8f03   \u6458\u8981\u7de8\u865f\uff1a8640  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Sarah Cannon Research Institute, Integra  2.\u00a0\u00a0\u00a0\u00a0 Paired matched normal sequencing to accurately identify somatic clonal hematopoiesis mutations (CHm) in solid tumor tissue and plasma specimens \u914d\u5c0d\u6b63\u5e38\u7d44\u7e54\u5b9a\u5e8f\u4ee5\u6e96\u78ba\u8b58\u5225\u5be6\u9ad4\u7624\u7d44\u7e54\u548c\u8840\u6f3f\u6a23\u672c\u4e2d\u7684\u9ad4\u7d30\u80de\u514b\u9686\u9020\u8840\u7a81\u8b8a\uff08CHm\uff09   \u6458\u8981\u7de8\u865f\uff1a 3051  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Eurofins, Mayo Clinic  3.\u00a0\u00a0\u00a0\u00a0 A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability \u57fa\u65bc\u591a\u7d44\u5b78\u751f\u7269\u6a19\u8a18\u7269\u7684\u6a5f\u5668\u5b78\u7fd2\u6f14\u7b97\u6cd5\u7528\u65bc\u6aa2\u6e2c\u816b\u7624\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\u6027   \u6458\u8981\u7de8\u865f\uff1a1554  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp  4.\u00a0\u00a0\u00a0\u00a0 Differences in baseline characteristics and healthcare costs among insured patients with advanced cancer with vs without clinical trial participation\u00a0\u00a0 \u6709\u7121\u81e8\u5e8a\u8a66\u9a57\u53c3\u8207\u7684\u665a\u671f\u764c\u75c7\u4fdd\u96aa\u60a3\u8005\u7684\u57fa\u7dda\u7279\u5fb5\u548c\u91ab\u7642\u6210\u672c\u5dee\u7570   \u6458\u8981\u7de8\u865f\uff1a11154  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Optum  5.\u00a0\u00a0\u00a0\u00a0 A highly sensitive, low input, and automated assay for molecular residual disease detection (MRD) using whole-genome sequencing (WGS)\u00a0\u00a0 \u57fa\u65bc\u5168\u57fa\u56e0\u7d44\u5b9a\u5e8f\uff08WGS\uff09\u7684\u9ad8\u9748\u654f\u5ea6\u3001\u4f4e\u6a23\u672c\u91cf\u3001\u81ea\u52d5\u5316\u7684\u5fae\u91cf\u6b98\u5b58\u75be\u75c5\uff08MRD\uff09\u6aa2\u6e2c\u65b9\u6cd5   \u6458\u8981\u7de8\u865f\uff1a3060  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d  6.\u00a0\u00a0\u00a0\u00a0 Comprehensive genomic and immune profiling of non-V600 BRAF-mutated melanomas: Implications for therapeutic strategies beyond BRAF\/MEK inhibitors \u975eV600 BRAF\u7a81\u8b8a\u9ed1\u8272\u7d20\u7624\u7684\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u548c\u514d\u75ab\u5206\u6790\uff1a\u5c0dBRAF\/MEK\u6291\u5236\u5291\u4ee5\u5916\u6cbb\u7642\u7b56\u7565\u7684\u555f\u793a   \u6458\u8981\u7de8\u865f\uff1ae21544  \u767c\u8868\u55ae\u4f4d\uff1aIIlumina \u56e0\u7f8e\u7d0d, Labcorp  7.\u00a0\u00a0\u00a0\u00a0 Multi-specimen comprehensive genomic profiling for diagnostic disambiguation in advanced and metastatic solid tumors Abstract\u00a0 \u591a\u6a23\u672c\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u5728\u665a\u671f\u548c\u8f49\u79fb\u6027\u5be6\u9ad4\u7624\u4e2d\u7684\u8a3a\u65b7\u89e3\u7591   \u6458\u8981\u7de8\u865f\uff1ae15166  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp  8.\u00a0\u00a0\u00a0\u00a0 Screening for social determinants of health among patients with advanced and metastatic cancer undergoing comprehensive genomic profiling in underserved communities \u5728\u4e0d\u767c\u9054\u793e\u5340\u4e2d\u63a5\u53d7\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u7684\u665a\u671f\u548c\u8f49\u79fb\u6027\u764c\u75c7\u60a3\u8005\u4e2d\u7be9\u67e5\u5065\u5eb7\u793e\u6703\u6c7a\u5b9a\u56e0\u7d20   \u6458\u8981\u7de8\u865f\uff1ae13545  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp  9.\u00a0\u00a0\u00a0\u00a0 Implementation of a comprehensive genomic profiling (CGP) panel for precision oncology at a cancer center in Brazil \u00a0 \u5728\u5df4\u897f\u4e00\u500b\u764c\u75c7\u4e2d\u5fc3\u5be6\u65bd\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u5c0f\u7d44\u4ee5\u5be6\u73fe\u7cbe\u6e96\u816b\u7624\u5b78   \u6458\u8981\u7de8\u865f\uff1ae23520  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, A.C. Camargo Cancer Center  10.\u00a0 Feasibility of implementing whole genome sequencing into routine oncology care \u5c07\u5168\u57fa\u56e0\u7d44\u5b9a\u5e8fWGS\u7d0d\u5165\u816b\u7624\u5e38\u898f\u8b77\u7406\u7684\u53ef\u884c\u6027   \u6458\u8981\u7de8\u865f\uff1ae15181  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d\uff0cWeill Cornell  11.\u00a0 Real-world costs and outcomes associated with biomarker testing by comprehensive genomic profiling (CGP) and non-CGP approaches among patients with metastatic non-small cell lung cancer (mNSCLC) \u5728\u8f49\u79fb\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\uff08mNSCLC\uff09\u60a3\u8005\u4e2d\uff0c\u901a\u904e\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u548c\u975eCGP\u65b9\u6cd5\u9032\u884c\u751f\u7269\u6a19\u8a18\u7269\u6aa2\u6e2c\u7684\u771f\u5be6\u4e16\u754c\u6210\u672c\u548c\u7372\u76ca   \u6458\u8981\u7de8\u865f\uff1ae20598  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Optum  12.\u00a0 CGP-based IO biomarker assessment and treatment utilization across a major US health system \u5728\u7f8e\u570b\u4e3b\u8981\u91ab\u7642\u7cfb\u7d71\u4e2d\u57fa\u65bcCGP\u7684IO\u816b\u7624\u514d\u75ab\u751f\u7269\u6a19\u8a18\u7269\u8a55\u4f30\u548c\u6cbb\u7642\u5229\u7528\u60c5\u6cc1\u00a0\u00a0   \u6458\u8981\u7de8\u865f\uff1ae23109  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Providence  13.\u00a0 NGS panels' capture of biomarkers associated with targeted therapies in clinical trials NGS panel\u6355\u7372\u8207\u81e8\u5e8a\u8a66\u9a57\u4e2d\u6a19\u9776\u6cbb\u7642\u76f8\u95dc\u7684\u751f\u7269\u6a19\u8a18\u7269\u00a0\u00a0   \u6458\u8981\u7de8\u865f\uff1ae13508  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d  14.\u00a0 Single point of entry to the European precision cancer medicine trial network PRIME-ROSE \u6b50\u6d32\u7cbe\u6e96\u764c\u75c7\u91ab\u5b78\u8a66\u9a57\u7db2\u8defPRIME-ROSE\u7684\u55ae\u4e00\u5165\u53e3\u9ede   \u6458\u8981\u7de8\u865f\uff1ae23024  \u767c\u8868\u55ae\u4f4d\uff1a IMPRESS Team  \u95dc\u65bcIllumina \u56e0\u7f8e\u7d0d Illumina\u81f4\u529b\u65bc\u63a8\u52d5\u548c\u6fc0\u767c\u57fa\u56e0\u7d44\u5b78\u7684\u767c\u5c55\u800c\u4e0d\u65b7\u6539\u5584\u4eba\u985e\u5065\u5eb7\u3002\u5c08\u6ce8\u5275\u65b0\u4f7f\u6211\u5011\u6210\u70ba\u5168\u7403\u57fa\u56e0\u5b9a\u5e8f\u548c\u6676\u7247\u6280\u8853\u7684\u9818\u5c0e\u8005\uff0c\u4e26\u70ba\u5168\u7403\u7bc4\u570d\u7684\u79d1\u7814\u3001\u81e8\u5e8a\u548c\u61c9\u7528\u5e02\u5834\u5ba2\u6236\u63d0\u4f9b\u5c08\u696d\u670d\u52d9\u3002\u6211\u5011\u7684\u7522\u54c1\u5ee3\u6cdb\u61c9\u7528\u65bc\u751f\u547d\u79d1\u5b78\u3001\u816b\u7624\u5b78\u3001\u751f\u6b96\u4fdd\u5065\u3001\u8fb2\u696d\u53ca\u5176\u4ed6\u65b0\u8208\u9818\u57df\u3002\u6b32\u77ad\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u8a2a\u554fwww.illumina.com\u3002 \u5728\u816b\u7624\u9818\u57df\uff0cIllumina\u56e0\u7f8e\u7d0d \u81f4\u529b\u65bc\u63a8\u52d5\u816b\u7624\u500b\u9ad4\u5316\u7684\u8b58\u5225\u8207\u6cbb\u7642\uff0c\u4ee5\u5275\u65b0\u6280\u8853\u52a0\u901f\u816b\u7624\u57fa\u56e0\u7d44\u5b78\u7684\u9769\u65b0\u3002\u6211\u5011\u7684\u6280\u8853\u5ee3\u6cdb\u61c9\u7528\u65bc\u816b\u7624\u57fa\u56e0\u7d44\u5b78\u7814\u7a76\uff0c\u75c5\u7406\u5b78\u8207\u816b\u7624\u81e8\u5e8a\u7814\u7a76\uff0c\u816b\u7624\u4f34\u96a8\u8a3a\u65b7\u4ee5\u53ca\u816b\u7624\u7cbe\u6e96\u91ab\u5b78\u7684\u672a\u4f86\u63a2\u7d22\u3002Illumina\u56e0\u7f8e\u7d0d\u5728\u816b\u7624\u9818\u57df\u7684\u7d42\u6975\u76ee\u6a19\u662f\uff1a\u901a\u904e\u79d1\u5b78\u767c\u73fe\u771f\u6b63\u6539\u8b8a\u816b\u7624\u60a3\u8005\u53ca\u5176\u5bb6\u5ead\u7684\u751f\u6d3b\u3002 \u672c\u6587\u4e2d\u6240\u63d0\u53ca\u7684\u6458\u8981\u5167\u5bb9\u5747\u4f86\u6e90\u65bc\u516c\u958b\u767c\u8868\u7684\u5b78\u8853\u6703\u8b70\u8cc7\u6599\u3002\u6211\u5011\u5df2\u76e1\u529b\u78ba\u4fdd\u6240\u5f15\u7528\u5167\u5bb9\u7684\u6e96\u78ba\u6027\uff0c\u4f46\u4e0d\u5c0d\u5176\u5b8c\u5168\u6e96\u78ba\u6027\u627f\u64d4\u4efb\u4f55\u8cac\u4efb\u3002\u8b80\u8005\u5728\u4f7f\u7528\u6216\u53c3\u8003\u8a72\u5167\u5bb9\u6642\uff0c\u61c9\u81ea\u884c\u6838\u5be6\u76f8\u95dc\u8cc7\u8a0a\u7684\u6e96\u78ba\u6027\uff0c\u4e26\u627f\u64d4\u76f8\u95dc\u98a8\u96aa\u3002\u4e0a\u8ff0\u6458\u8981\u5167\u5bb9\u7684\u7248\u6b0a\u548c\u667a\u6167\u8ca1\u7522\u6b0a\u6b78\u539f\u4f5c\u8005\u6216\u76f8\u95dc\u6a5f\u69cb\u6240\u6709\u3002","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pingtungtimes.com.tw\/?p=240126","og_locale":"zh_TW","og_type":"article","og_title":"ASCO 2024\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u4e28Illumina\u56e0\u7f8e\u7d0d \u6700\u65b0\u7814\u7a76\u63a8\u52d5\u57fa\u56e0\u6aa2\u6e2c\u6210\u70ba\u764c\u75c7\u6cbb\u7642\u6a19\u6e96\u6d41\u7a0b - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","og_description":"\u53f0\u53172024\u5e745\u670831\u65e5 \/\u7f8e\u901a\u793e\/ -- \u5168\u7403\u77da\u76ee\u7684\u816b\u7624\u76db\u6703ASCO 2024\u5c07\u65bc\u7576\u5730\u6642\u95935\u670831\u65e5\u81f36\u67084\u65e5\u5728\u7f8e\u570b\u829d\u52a0\u54e5\u8209\u884c\uff0cIllumina \u56e0\u7f8e\u7d0d14\u9805\u6700\u65b0\u7814\u7a76\u5c07\u4eae\u76f8\u672c\u6b21\u5927\u6703\u3002\u4f5c\u70ba\u5168\u7403\u57fa\u56e0\u5b9a\u5e8f\u548c\u6676\u7247\u6280\u8853\u7684\u9818\u5c0e\u8005\uff0cIllumina\u56e0\u7f8e\u7d0d\u5728ASCO 2024\u4e2d\u651c\u624b\u570b\u969b\u77e5\u540d\u81e8\u5e8a\u5925\u4f34\uff0c\u5c07\u5e36\u4f86\u54ea\u4e9b\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u9032\u5c55\uff0c\u8b93\u6211\u5011\u4eca\u5929\u5148\u7779\u70ba\u5feb\u3002     \u4eae\u9ede\uff08Transform oncology with genomics\uff09\uff1a   \u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c (CGP) \u512a\u65bc\u55ae\u57fa\u56e0\u6aa2\u6e2c (SGT) \u7684\u66f4\u591a\u81e8\u5e8a\u5be6\u7528\u6027\u8b49\u64da\uff1b  Illumina\u56e0\u7f8e\u7d0d MRD\uff08\u5fae\u91cf\u6b98\u5b58\u75be\u75c5\uff09\u6aa2\u6e2c\u65b0\u9032\u5c55\uff1b  \u591a\u9805\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff0c\u6d88\u9664\u5e02\u5834\u51c6\u5165\u969c\u7919\uff1b  \u5ee3\u6cdb\u578b\u8b8a\u7570\u548c\u514d\u75ab\u5206\u6790 (CGIP) \u57fa\u65bc\u591a\u7d44\u5b78\u8cc7\u6599\u66f4\u597d\u8a55\u4f30\u816b\u7624\u514d\u75ab\uff1b  \u63a2\u7d22\u5168\u57fa\u56e0\u7d44\u6e2c\u5e8fWGS\u5728\u816b\u7624\u5e38\u898f\u81e8\u5e8a\u6aa2\u6e2c\u4e2d\u7684\u53ef\u884c\u6027\uff1b  \u540c\u6642\uff0cIllumina \u56e0\u7f8e\u7d0d\u00a0\u5c07\u5728ASCO\u5927\u6703\u73fe\u5834\u8a2d\u7acb\u6524\u4f4d\uff08\u6524\u4f4d\u865f\uff1a35103\uff09\uff0c\u8aa0\u646f\u9080\u8acb\u60a8\u73fe\u5834\u849e\u81e8\u4ea4\u6d41\uff01 Illumina \u56e0\u7f8e\u7d0d\u00a0ASCO 2024 \u7814\u7a76\u84cb\u89bd 1.\u00a0\u00a0\u00a0\u00a0 Performance of comprehensive genomic profiling (CGP) versus single gene testing (SGT) in guideline-recommended biomarker selection in non-small cell lung cancer (NSCLC) \u975e\u5c0f\u578b\u7d30\u80de\u80ba\u764c\uff08NSCLC\uff09\u4e2d\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u8207\u55ae\u57fa\u56e0\u6aa2\u6e2c\uff08SGT\uff09\u5728\u6307\u5f15\u63a8\u85a6\u751f\u7269\u6a19\u8a18\u7269\u9078\u64c7\u4e2d\u7684\u6027\u80fd\u6bd4\u8f03   \u6458\u8981\u7de8\u865f\uff1a8640  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Sarah Cannon Research Institute, Integra  2.\u00a0\u00a0\u00a0\u00a0 Paired matched normal sequencing to accurately identify somatic clonal hematopoiesis mutations (CHm) in solid tumor tissue and plasma specimens \u914d\u5c0d\u6b63\u5e38\u7d44\u7e54\u5b9a\u5e8f\u4ee5\u6e96\u78ba\u8b58\u5225\u5be6\u9ad4\u7624\u7d44\u7e54\u548c\u8840\u6f3f\u6a23\u672c\u4e2d\u7684\u9ad4\u7d30\u80de\u514b\u9686\u9020\u8840\u7a81\u8b8a\uff08CHm\uff09   \u6458\u8981\u7de8\u865f\uff1a 3051  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Eurofins, Mayo Clinic  3.\u00a0\u00a0\u00a0\u00a0 A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability \u57fa\u65bc\u591a\u7d44\u5b78\u751f\u7269\u6a19\u8a18\u7269\u7684\u6a5f\u5668\u5b78\u7fd2\u6f14\u7b97\u6cd5\u7528\u65bc\u6aa2\u6e2c\u816b\u7624\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\u6027   \u6458\u8981\u7de8\u865f\uff1a1554  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp  4.\u00a0\u00a0\u00a0\u00a0 Differences in baseline characteristics and healthcare costs among insured patients with advanced cancer with vs without clinical trial participation\u00a0\u00a0 \u6709\u7121\u81e8\u5e8a\u8a66\u9a57\u53c3\u8207\u7684\u665a\u671f\u764c\u75c7\u4fdd\u96aa\u60a3\u8005\u7684\u57fa\u7dda\u7279\u5fb5\u548c\u91ab\u7642\u6210\u672c\u5dee\u7570   \u6458\u8981\u7de8\u865f\uff1a11154  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Optum  5.\u00a0\u00a0\u00a0\u00a0 A highly sensitive, low input, and automated assay for molecular residual disease detection (MRD) using whole-genome sequencing (WGS)\u00a0\u00a0 \u57fa\u65bc\u5168\u57fa\u56e0\u7d44\u5b9a\u5e8f\uff08WGS\uff09\u7684\u9ad8\u9748\u654f\u5ea6\u3001\u4f4e\u6a23\u672c\u91cf\u3001\u81ea\u52d5\u5316\u7684\u5fae\u91cf\u6b98\u5b58\u75be\u75c5\uff08MRD\uff09\u6aa2\u6e2c\u65b9\u6cd5   \u6458\u8981\u7de8\u865f\uff1a3060  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d  6.\u00a0\u00a0\u00a0\u00a0 Comprehensive genomic and immune profiling of non-V600 BRAF-mutated melanomas: Implications for therapeutic strategies beyond BRAF\/MEK inhibitors \u975eV600 BRAF\u7a81\u8b8a\u9ed1\u8272\u7d20\u7624\u7684\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u548c\u514d\u75ab\u5206\u6790\uff1a\u5c0dBRAF\/MEK\u6291\u5236\u5291\u4ee5\u5916\u6cbb\u7642\u7b56\u7565\u7684\u555f\u793a   \u6458\u8981\u7de8\u865f\uff1ae21544  \u767c\u8868\u55ae\u4f4d\uff1aIIlumina \u56e0\u7f8e\u7d0d, Labcorp  7.\u00a0\u00a0\u00a0\u00a0 Multi-specimen comprehensive genomic profiling for diagnostic disambiguation in advanced and metastatic solid tumors Abstract\u00a0 \u591a\u6a23\u672c\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u5728\u665a\u671f\u548c\u8f49\u79fb\u6027\u5be6\u9ad4\u7624\u4e2d\u7684\u8a3a\u65b7\u89e3\u7591   \u6458\u8981\u7de8\u865f\uff1ae15166  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp  8.\u00a0\u00a0\u00a0\u00a0 Screening for social determinants of health among patients with advanced and metastatic cancer undergoing comprehensive genomic profiling in underserved communities \u5728\u4e0d\u767c\u9054\u793e\u5340\u4e2d\u63a5\u53d7\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u7684\u665a\u671f\u548c\u8f49\u79fb\u6027\u764c\u75c7\u60a3\u8005\u4e2d\u7be9\u67e5\u5065\u5eb7\u793e\u6703\u6c7a\u5b9a\u56e0\u7d20   \u6458\u8981\u7de8\u865f\uff1ae13545  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp  9.\u00a0\u00a0\u00a0\u00a0 Implementation of a comprehensive genomic profiling (CGP) panel for precision oncology at a cancer center in Brazil \u00a0 \u5728\u5df4\u897f\u4e00\u500b\u764c\u75c7\u4e2d\u5fc3\u5be6\u65bd\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u5c0f\u7d44\u4ee5\u5be6\u73fe\u7cbe\u6e96\u816b\u7624\u5b78   \u6458\u8981\u7de8\u865f\uff1ae23520  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, A.C. Camargo Cancer Center  10.\u00a0 Feasibility of implementing whole genome sequencing into routine oncology care \u5c07\u5168\u57fa\u56e0\u7d44\u5b9a\u5e8fWGS\u7d0d\u5165\u816b\u7624\u5e38\u898f\u8b77\u7406\u7684\u53ef\u884c\u6027   \u6458\u8981\u7de8\u865f\uff1ae15181  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d\uff0cWeill Cornell  11.\u00a0 Real-world costs and outcomes associated with biomarker testing by comprehensive genomic profiling (CGP) and non-CGP approaches among patients with metastatic non-small cell lung cancer (mNSCLC) \u5728\u8f49\u79fb\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\uff08mNSCLC\uff09\u60a3\u8005\u4e2d\uff0c\u901a\u904e\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u548c\u975eCGP\u65b9\u6cd5\u9032\u884c\u751f\u7269\u6a19\u8a18\u7269\u6aa2\u6e2c\u7684\u771f\u5be6\u4e16\u754c\u6210\u672c\u548c\u7372\u76ca   \u6458\u8981\u7de8\u865f\uff1ae20598  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Optum  12.\u00a0 CGP-based IO biomarker assessment and treatment utilization across a major US health system \u5728\u7f8e\u570b\u4e3b\u8981\u91ab\u7642\u7cfb\u7d71\u4e2d\u57fa\u65bcCGP\u7684IO\u816b\u7624\u514d\u75ab\u751f\u7269\u6a19\u8a18\u7269\u8a55\u4f30\u548c\u6cbb\u7642\u5229\u7528\u60c5\u6cc1\u00a0\u00a0   \u6458\u8981\u7de8\u865f\uff1ae23109  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Providence  13.\u00a0 NGS panels' capture of biomarkers associated with targeted therapies in clinical trials NGS panel\u6355\u7372\u8207\u81e8\u5e8a\u8a66\u9a57\u4e2d\u6a19\u9776\u6cbb\u7642\u76f8\u95dc\u7684\u751f\u7269\u6a19\u8a18\u7269\u00a0\u00a0   \u6458\u8981\u7de8\u865f\uff1ae13508  \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d  14.\u00a0 Single point of entry to the European precision cancer medicine trial network PRIME-ROSE \u6b50\u6d32\u7cbe\u6e96\u764c\u75c7\u91ab\u5b78\u8a66\u9a57\u7db2\u8defPRIME-ROSE\u7684\u55ae\u4e00\u5165\u53e3\u9ede   \u6458\u8981\u7de8\u865f\uff1ae23024  \u767c\u8868\u55ae\u4f4d\uff1a IMPRESS Team  \u95dc\u65bcIllumina \u56e0\u7f8e\u7d0d Illumina\u81f4\u529b\u65bc\u63a8\u52d5\u548c\u6fc0\u767c\u57fa\u56e0\u7d44\u5b78\u7684\u767c\u5c55\u800c\u4e0d\u65b7\u6539\u5584\u4eba\u985e\u5065\u5eb7\u3002\u5c08\u6ce8\u5275\u65b0\u4f7f\u6211\u5011\u6210\u70ba\u5168\u7403\u57fa\u56e0\u5b9a\u5e8f\u548c\u6676\u7247\u6280\u8853\u7684\u9818\u5c0e\u8005\uff0c\u4e26\u70ba\u5168\u7403\u7bc4\u570d\u7684\u79d1\u7814\u3001\u81e8\u5e8a\u548c\u61c9\u7528\u5e02\u5834\u5ba2\u6236\u63d0\u4f9b\u5c08\u696d\u670d\u52d9\u3002\u6211\u5011\u7684\u7522\u54c1\u5ee3\u6cdb\u61c9\u7528\u65bc\u751f\u547d\u79d1\u5b78\u3001\u816b\u7624\u5b78\u3001\u751f\u6b96\u4fdd\u5065\u3001\u8fb2\u696d\u53ca\u5176\u4ed6\u65b0\u8208\u9818\u57df\u3002\u6b32\u77ad\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u8a2a\u554fwww.illumina.com\u3002 \u5728\u816b\u7624\u9818\u57df\uff0cIllumina\u56e0\u7f8e\u7d0d \u81f4\u529b\u65bc\u63a8\u52d5\u816b\u7624\u500b\u9ad4\u5316\u7684\u8b58\u5225\u8207\u6cbb\u7642\uff0c\u4ee5\u5275\u65b0\u6280\u8853\u52a0\u901f\u816b\u7624\u57fa\u56e0\u7d44\u5b78\u7684\u9769\u65b0\u3002\u6211\u5011\u7684\u6280\u8853\u5ee3\u6cdb\u61c9\u7528\u65bc\u816b\u7624\u57fa\u56e0\u7d44\u5b78\u7814\u7a76\uff0c\u75c5\u7406\u5b78\u8207\u816b\u7624\u81e8\u5e8a\u7814\u7a76\uff0c\u816b\u7624\u4f34\u96a8\u8a3a\u65b7\u4ee5\u53ca\u816b\u7624\u7cbe\u6e96\u91ab\u5b78\u7684\u672a\u4f86\u63a2\u7d22\u3002Illumina\u56e0\u7f8e\u7d0d\u5728\u816b\u7624\u9818\u57df\u7684\u7d42\u6975\u76ee\u6a19\u662f\uff1a\u901a\u904e\u79d1\u5b78\u767c\u73fe\u771f\u6b63\u6539\u8b8a\u816b\u7624\u60a3\u8005\u53ca\u5176\u5bb6\u5ead\u7684\u751f\u6d3b\u3002 \u672c\u6587\u4e2d\u6240\u63d0\u53ca\u7684\u6458\u8981\u5167\u5bb9\u5747\u4f86\u6e90\u65bc\u516c\u958b\u767c\u8868\u7684\u5b78\u8853\u6703\u8b70\u8cc7\u6599\u3002\u6211\u5011\u5df2\u76e1\u529b\u78ba\u4fdd\u6240\u5f15\u7528\u5167\u5bb9\u7684\u6e96\u78ba\u6027\uff0c\u4f46\u4e0d\u5c0d\u5176\u5b8c\u5168\u6e96\u78ba\u6027\u627f\u64d4\u4efb\u4f55\u8cac\u4efb\u3002\u8b80\u8005\u5728\u4f7f\u7528\u6216\u53c3\u8003\u8a72\u5167\u5bb9\u6642\uff0c\u61c9\u81ea\u884c\u6838\u5be6\u76f8\u95dc\u8cc7\u8a0a\u7684\u6e96\u78ba\u6027\uff0c\u4e26\u627f\u64d4\u76f8\u95dc\u98a8\u96aa\u3002\u4e0a\u8ff0\u6458\u8981\u5167\u5bb9\u7684\u7248\u6b0a\u548c\u667a\u6167\u8ca1\u7522\u6b0a\u6b78\u539f\u4f5c\u8005\u6216\u76f8\u95dc\u6a5f\u69cb\u6240\u6709\u3002","og_url":"https:\/\/pingtungtimes.com.tw\/?p=240126","og_site_name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","article_publisher":"https:\/\/www.facebook.com\/pingtungnews","article_published_time":"2024-05-31T11:30:00+00:00","og_image":[{"width":400,"height":97,"url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2024\/05\/illumina_full_logo_RGB_pumpkin_Logo-1.jpg","type":"image\/jpeg"}],"author":"\u7f8e\u901a\u793e","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005:":"\u7f8e\u901a\u793e","\u9810\u4f30\u95b1\u8b80\u6642\u9593":"2 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/pingtungtimes.com.tw\/?p=240126#article","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=240126"},"author":{"name":"\u7f8e\u901a\u793e","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3"},"headline":"ASCO 2024\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u4e28Illumina\u56e0\u7f8e\u7d0d \u6700\u65b0\u7814\u7a76\u63a8\u52d5\u57fa\u56e0\u6aa2\u6e2c\u6210\u70ba\u764c\u75c7\u6cbb\u7642\u6a19\u6e96\u6d41\u7a0b","datePublished":"2024-05-31T11:30:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=240126"},"wordCount":327,"publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=240126#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2024\/05\/illumina_full_logo_RGB_pumpkin_Logo-1.jpg","articleSection":["\u7f8e\u901a\u793e"],"inLanguage":"zh-TW"},{"@type":"WebPage","@id":"https:\/\/pingtungtimes.com.tw\/?p=240126","url":"https:\/\/pingtungtimes.com.tw\/?p=240126","name":"ASCO 2024\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u4e28Illumina\u56e0\u7f8e\u7d0d \u6700\u65b0\u7814\u7a76\u63a8\u52d5\u57fa\u56e0\u6aa2\u6e2c\u6210\u70ba\u764c\u75c7\u6cbb\u7642\u6a19\u6e96\u6d41\u7a0b - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=240126#primaryimage"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=240126#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2024\/05\/illumina_full_logo_RGB_pumpkin_Logo-1.jpg","datePublished":"2024-05-31T11:30:00+00:00","description":"\u53f0\u53172024\u5e745\u670831\u65e5 \/\u7f8e\u901a\u793e\/ -- \u5168\u7403\u77da\u76ee\u7684\u816b\u7624\u76db\u6703ASCO 2024\u5c07\u65bc\u7576\u5730\u6642\u95935\u670831\u65e5\u81f36\u67084\u65e5\u5728\u7f8e\u570b\u829d\u52a0\u54e5\u8209\u884c\uff0cIllumina \u56e0\u7f8e\u7d0d14\u9805\u6700\u65b0\u7814\u7a76\u5c07\u4eae\u76f8\u672c\u6b21\u5927\u6703\u3002\u4f5c\u70ba\u5168\u7403\u57fa\u56e0\u5b9a\u5e8f\u548c\u6676\u7247\u6280\u8853\u7684\u9818\u5c0e\u8005\uff0cIllumina\u56e0\u7f8e\u7d0d\u5728ASCO 2024\u4e2d\u651c\u624b\u570b\u969b\u77e5\u540d\u81e8\u5e8a\u5925\u4f34\uff0c\u5c07\u5e36\u4f86\u54ea\u4e9b\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u9032\u5c55\uff0c\u8b93\u6211\u5011\u4eca\u5929\u5148\u7779\u70ba\u5feb\u3002 \u4eae\u9ede\uff08Transform oncology with genomics\uff09\uff1a \u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c (CGP) \u512a\u65bc\u55ae\u57fa\u56e0\u6aa2\u6e2c (SGT) \u7684\u66f4\u591a\u81e8\u5e8a\u5be6\u7528\u6027\u8b49\u64da\uff1b Illumina\u56e0\u7f8e\u7d0d MRD\uff08\u5fae\u91cf\u6b98\u5b58\u75be\u75c5\uff09\u6aa2\u6e2c\u65b0\u9032\u5c55\uff1b \u591a\u9805\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff0c\u6d88\u9664\u5e02\u5834\u51c6\u5165\u969c\u7919\uff1b \u5ee3\u6cdb\u578b\u8b8a\u7570\u548c\u514d\u75ab\u5206\u6790 (CGIP) \u57fa\u65bc\u591a\u7d44\u5b78\u8cc7\u6599\u66f4\u597d\u8a55\u4f30\u816b\u7624\u514d\u75ab\uff1b \u63a2\u7d22\u5168\u57fa\u56e0\u7d44\u6e2c\u5e8fWGS\u5728\u816b\u7624\u5e38\u898f\u81e8\u5e8a\u6aa2\u6e2c\u4e2d\u7684\u53ef\u884c\u6027\uff1b \u540c\u6642\uff0cIllumina \u56e0\u7f8e\u7d0d\u00a0\u5c07\u5728ASCO\u5927\u6703\u73fe\u5834\u8a2d\u7acb\u6524\u4f4d\uff08\u6524\u4f4d\u865f\uff1a35103\uff09\uff0c\u8aa0\u646f\u9080\u8acb\u60a8\u73fe\u5834\u849e\u81e8\u4ea4\u6d41\uff01 Illumina \u56e0\u7f8e\u7d0d\u00a0ASCO 2024 \u7814\u7a76\u84cb\u89bd 1.\u00a0\u00a0\u00a0\u00a0 Performance of comprehensive genomic profiling (CGP) versus single gene testing (SGT) in guideline-recommended biomarker selection in non-small cell lung cancer (NSCLC) \u975e\u5c0f\u578b\u7d30\u80de\u80ba\u764c\uff08NSCLC\uff09\u4e2d\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u8207\u55ae\u57fa\u56e0\u6aa2\u6e2c\uff08SGT\uff09\u5728\u6307\u5f15\u63a8\u85a6\u751f\u7269\u6a19\u8a18\u7269\u9078\u64c7\u4e2d\u7684\u6027\u80fd\u6bd4\u8f03 \u6458\u8981\u7de8\u865f\uff1a8640 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Sarah Cannon Research Institute, Integra 2.\u00a0\u00a0\u00a0\u00a0 Paired matched normal sequencing to accurately identify somatic clonal hematopoiesis mutations (CHm) in solid tumor tissue and plasma specimens \u914d\u5c0d\u6b63\u5e38\u7d44\u7e54\u5b9a\u5e8f\u4ee5\u6e96\u78ba\u8b58\u5225\u5be6\u9ad4\u7624\u7d44\u7e54\u548c\u8840\u6f3f\u6a23\u672c\u4e2d\u7684\u9ad4\u7d30\u80de\u514b\u9686\u9020\u8840\u7a81\u8b8a\uff08CHm\uff09 \u6458\u8981\u7de8\u865f\uff1a 3051 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Eurofins, Mayo Clinic 3.\u00a0\u00a0\u00a0\u00a0 A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability \u57fa\u65bc\u591a\u7d44\u5b78\u751f\u7269\u6a19\u8a18\u7269\u7684\u6a5f\u5668\u5b78\u7fd2\u6f14\u7b97\u6cd5\u7528\u65bc\u6aa2\u6e2c\u816b\u7624\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\u6027 \u6458\u8981\u7de8\u865f\uff1a1554 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp 4.\u00a0\u00a0\u00a0\u00a0 Differences in baseline characteristics and healthcare costs among insured patients with advanced cancer with vs without clinical trial participation\u00a0\u00a0 \u6709\u7121\u81e8\u5e8a\u8a66\u9a57\u53c3\u8207\u7684\u665a\u671f\u764c\u75c7\u4fdd\u96aa\u60a3\u8005\u7684\u57fa\u7dda\u7279\u5fb5\u548c\u91ab\u7642\u6210\u672c\u5dee\u7570 \u6458\u8981\u7de8\u865f\uff1a11154 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Optum 5.\u00a0\u00a0\u00a0\u00a0 A highly sensitive, low input, and automated assay for molecular residual disease detection (MRD) using whole-genome sequencing (WGS)\u00a0\u00a0 \u57fa\u65bc\u5168\u57fa\u56e0\u7d44\u5b9a\u5e8f\uff08WGS\uff09\u7684\u9ad8\u9748\u654f\u5ea6\u3001\u4f4e\u6a23\u672c\u91cf\u3001\u81ea\u52d5\u5316\u7684\u5fae\u91cf\u6b98\u5b58\u75be\u75c5\uff08MRD\uff09\u6aa2\u6e2c\u65b9\u6cd5 \u6458\u8981\u7de8\u865f\uff1a3060 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d 6.\u00a0\u00a0\u00a0\u00a0 Comprehensive genomic and immune profiling of non-V600 BRAF-mutated melanomas: Implications for therapeutic strategies beyond BRAF\/MEK inhibitors \u975eV600 BRAF\u7a81\u8b8a\u9ed1\u8272\u7d20\u7624\u7684\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u548c\u514d\u75ab\u5206\u6790\uff1a\u5c0dBRAF\/MEK\u6291\u5236\u5291\u4ee5\u5916\u6cbb\u7642\u7b56\u7565\u7684\u555f\u793a \u6458\u8981\u7de8\u865f\uff1ae21544 \u767c\u8868\u55ae\u4f4d\uff1aIIlumina \u56e0\u7f8e\u7d0d, Labcorp 7.\u00a0\u00a0\u00a0\u00a0 Multi-specimen comprehensive genomic profiling for diagnostic disambiguation in advanced and metastatic solid tumors Abstract\u00a0 \u591a\u6a23\u672c\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u5728\u665a\u671f\u548c\u8f49\u79fb\u6027\u5be6\u9ad4\u7624\u4e2d\u7684\u8a3a\u65b7\u89e3\u7591 \u6458\u8981\u7de8\u865f\uff1ae15166 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp 8.\u00a0\u00a0\u00a0\u00a0 Screening for social determinants of health among patients with advanced and metastatic cancer undergoing comprehensive genomic profiling in underserved communities \u5728\u4e0d\u767c\u9054\u793e\u5340\u4e2d\u63a5\u53d7\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\u7684\u665a\u671f\u548c\u8f49\u79fb\u6027\u764c\u75c7\u60a3\u8005\u4e2d\u7be9\u67e5\u5065\u5eb7\u793e\u6703\u6c7a\u5b9a\u56e0\u7d20 \u6458\u8981\u7de8\u865f\uff1ae13545 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Labcorp 9.\u00a0\u00a0\u00a0\u00a0 Implementation of a comprehensive genomic profiling (CGP) panel for precision oncology at a cancer center in Brazil \u00a0 \u5728\u5df4\u897f\u4e00\u500b\u764c\u75c7\u4e2d\u5fc3\u5be6\u65bd\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u5c0f\u7d44\u4ee5\u5be6\u73fe\u7cbe\u6e96\u816b\u7624\u5b78 \u6458\u8981\u7de8\u865f\uff1ae23520 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, A.C. Camargo Cancer Center 10.\u00a0 Feasibility of implementing whole genome sequencing into routine oncology care \u5c07\u5168\u57fa\u56e0\u7d44\u5b9a\u5e8fWGS\u7d0d\u5165\u816b\u7624\u5e38\u898f\u8b77\u7406\u7684\u53ef\u884c\u6027 \u6458\u8981\u7de8\u865f\uff1ae15181 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d\uff0cWeill Cornell 11.\u00a0 Real-world costs and outcomes associated with biomarker testing by comprehensive genomic profiling (CGP) and non-CGP approaches among patients with metastatic non-small cell lung cancer (mNSCLC) \u5728\u8f49\u79fb\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\uff08mNSCLC\uff09\u60a3\u8005\u4e2d\uff0c\u901a\u904e\u5ee3\u6cdb\u578b\u57fa\u56e0\u6aa2\u6e2c\uff08CGP\uff09\u548c\u975eCGP\u65b9\u6cd5\u9032\u884c\u751f\u7269\u6a19\u8a18\u7269\u6aa2\u6e2c\u7684\u771f\u5be6\u4e16\u754c\u6210\u672c\u548c\u7372\u76ca \u6458\u8981\u7de8\u865f\uff1ae20598 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Optum 12.\u00a0 CGP-based IO biomarker assessment and treatment utilization across a major US health system \u5728\u7f8e\u570b\u4e3b\u8981\u91ab\u7642\u7cfb\u7d71\u4e2d\u57fa\u65bcCGP\u7684IO\u816b\u7624\u514d\u75ab\u751f\u7269\u6a19\u8a18\u7269\u8a55\u4f30\u548c\u6cbb\u7642\u5229\u7528\u60c5\u6cc1\u00a0\u00a0 \u6458\u8981\u7de8\u865f\uff1ae23109 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d, Providence 13.\u00a0 NGS panels' capture of biomarkers associated with targeted therapies in clinical trials NGS panel\u6355\u7372\u8207\u81e8\u5e8a\u8a66\u9a57\u4e2d\u6a19\u9776\u6cbb\u7642\u76f8\u95dc\u7684\u751f\u7269\u6a19\u8a18\u7269\u00a0\u00a0 \u6458\u8981\u7de8\u865f\uff1ae13508 \u767c\u8868\u55ae\u4f4d\uff1a Illumina \u56e0\u7f8e\u7d0d 14.\u00a0 Single point of entry to the European precision cancer medicine trial network PRIME-ROSE \u6b50\u6d32\u7cbe\u6e96\u764c\u75c7\u91ab\u5b78\u8a66\u9a57\u7db2\u8defPRIME-ROSE\u7684\u55ae\u4e00\u5165\u53e3\u9ede \u6458\u8981\u7de8\u865f\uff1ae23024 \u767c\u8868\u55ae\u4f4d\uff1a IMPRESS Team \u95dc\u65bcIllumina \u56e0\u7f8e\u7d0d Illumina\u81f4\u529b\u65bc\u63a8\u52d5\u548c\u6fc0\u767c\u57fa\u56e0\u7d44\u5b78\u7684\u767c\u5c55\u800c\u4e0d\u65b7\u6539\u5584\u4eba\u985e\u5065\u5eb7\u3002\u5c08\u6ce8\u5275\u65b0\u4f7f\u6211\u5011\u6210\u70ba\u5168\u7403\u57fa\u56e0\u5b9a\u5e8f\u548c\u6676\u7247\u6280\u8853\u7684\u9818\u5c0e\u8005\uff0c\u4e26\u70ba\u5168\u7403\u7bc4\u570d\u7684\u79d1\u7814\u3001\u81e8\u5e8a\u548c\u61c9\u7528\u5e02\u5834\u5ba2\u6236\u63d0\u4f9b\u5c08\u696d\u670d\u52d9\u3002\u6211\u5011\u7684\u7522\u54c1\u5ee3\u6cdb\u61c9\u7528\u65bc\u751f\u547d\u79d1\u5b78\u3001\u816b\u7624\u5b78\u3001\u751f\u6b96\u4fdd\u5065\u3001\u8fb2\u696d\u53ca\u5176\u4ed6\u65b0\u8208\u9818\u57df\u3002\u6b32\u77ad\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u8a2a\u554fwww.illumina.com\u3002 \u5728\u816b\u7624\u9818\u57df\uff0cIllumina\u56e0\u7f8e\u7d0d \u81f4\u529b\u65bc\u63a8\u52d5\u816b\u7624\u500b\u9ad4\u5316\u7684\u8b58\u5225\u8207\u6cbb\u7642\uff0c\u4ee5\u5275\u65b0\u6280\u8853\u52a0\u901f\u816b\u7624\u57fa\u56e0\u7d44\u5b78\u7684\u9769\u65b0\u3002\u6211\u5011\u7684\u6280\u8853\u5ee3\u6cdb\u61c9\u7528\u65bc\u816b\u7624\u57fa\u56e0\u7d44\u5b78\u7814\u7a76\uff0c\u75c5\u7406\u5b78\u8207\u816b\u7624\u81e8\u5e8a\u7814\u7a76\uff0c\u816b\u7624\u4f34\u96a8\u8a3a\u65b7\u4ee5\u53ca\u816b\u7624\u7cbe\u6e96\u91ab\u5b78\u7684\u672a\u4f86\u63a2\u7d22\u3002Illumina\u56e0\u7f8e\u7d0d\u5728\u816b\u7624\u9818\u57df\u7684\u7d42\u6975\u76ee\u6a19\u662f\uff1a\u901a\u904e\u79d1\u5b78\u767c\u73fe\u771f\u6b63\u6539\u8b8a\u816b\u7624\u60a3\u8005\u53ca\u5176\u5bb6\u5ead\u7684\u751f\u6d3b\u3002 \u672c\u6587\u4e2d\u6240\u63d0\u53ca\u7684\u6458\u8981\u5167\u5bb9\u5747\u4f86\u6e90\u65bc\u516c\u958b\u767c\u8868\u7684\u5b78\u8853\u6703\u8b70\u8cc7\u6599\u3002\u6211\u5011\u5df2\u76e1\u529b\u78ba\u4fdd\u6240\u5f15\u7528\u5167\u5bb9\u7684\u6e96\u78ba\u6027\uff0c\u4f46\u4e0d\u5c0d\u5176\u5b8c\u5168\u6e96\u78ba\u6027\u627f\u64d4\u4efb\u4f55\u8cac\u4efb\u3002\u8b80\u8005\u5728\u4f7f\u7528\u6216\u53c3\u8003\u8a72\u5167\u5bb9\u6642\uff0c\u61c9\u81ea\u884c\u6838\u5be6\u76f8\u95dc\u8cc7\u8a0a\u7684\u6e96\u78ba\u6027\uff0c\u4e26\u627f\u64d4\u76f8\u95dc\u98a8\u96aa\u3002\u4e0a\u8ff0\u6458\u8981\u5167\u5bb9\u7684\u7248\u6b0a\u548c\u667a\u6167\u8ca1\u7522\u6b0a\u6b78\u539f\u4f5c\u8005\u6216\u76f8\u95dc\u6a5f\u69cb\u6240\u6709\u3002","breadcrumb":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=240126#breadcrumb"},"inLanguage":"zh-TW","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pingtungtimes.com.tw\/?p=240126"]}]},{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/?p=240126#primaryimage","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2024\/05\/illumina_full_logo_RGB_pumpkin_Logo-1.jpg","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2024\/05\/illumina_full_logo_RGB_pumpkin_Logo-1.jpg","width":400,"height":97},{"@type":"BreadcrumbList","@id":"https:\/\/pingtungtimes.com.tw\/?p=240126#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/pingtungtimes.com.tw\/"},{"@type":"ListItem","position":2,"name":"ASCO 2024\u7cbe\u6e96\u91ab\u5b78\u524d\u6cbf\u4e28Illumina\u56e0\u7f8e\u7d0d \u6700\u65b0\u7814\u7a76\u63a8\u52d5\u57fa\u56e0\u6aa2\u6e2c\u6210\u70ba\u764c\u75c7\u6cbb\u7642\u6a19\u6e96\u6d41\u7a0b"}]},{"@type":"WebSite","@id":"https:\/\/pingtungtimes.com.tw\/#website","url":"https:\/\/pingtungtimes.com.tw\/","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4","publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pingtungtimes.com.tw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-TW"},{"@type":"Organization","@id":"https:\/\/pingtungtimes.com.tw\/#organization","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","url":"https:\/\/pingtungtimes.com.tw\/","logo":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":150,"height":150,"caption":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pingtungnews"]},{"@type":"Person","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3","name":"\u7f8e\u901a\u793e","image":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","caption":"\u7f8e\u901a\u793e"},"url":"https:\/\/pingtungtimes.com.tw\/?author=16"}]}},"_links":{"self":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/240126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=240126"}],"version-history":[{"count":0,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/240126\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/media\/240127"}],"wp:attachment":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=240126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=240126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=240126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}